Culture medium and method for producing pancreatic organoids in vitro
A 3D culture method using Matrigel and specific growth factors supports the expansion and differentiation of pancreatic organoids with functional β cells, addressing the inefficiencies of current strategies and offering therapeutic and screening applications.
Patent Information
- Application Number
- CN202410928457.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-09-17
- Filing Date
- 2020-09-17
- Publication Date
- 2024-12-06
AI Technical Summary
Existing methods struggle to effectively produce and expand pancreatic β cells in vitro for cell therapy alternatives to treat diabetes, as current tissue culture strategies are inefficient and limited in expanding and differentiating progenitors into β-like cells.
A method involving the culture of endocrine progenitor cells in a 3D organoid culture medium, using Matrigel or hydrogels, supplemented with growth factors and inhibitors, to produce pancreatic organoids containing functional β cells, utilizing fluorescence-assisted cell sorting (FACS) for isolation.
The method enables the long-term expansion and differentiation of pancreatic organoids with functional β cells, capable of detecting glucose and secreting insulin, and demonstrates potential therapeutic applications in diabetes treatment and in vitro screening.
Smart Images

Figure SMS_3 
Figure SMS_4 
Figure SMS_5
Abstract
Description
[0001] This divisional application is a divisional application of the invention patent application with international application number PCT / CN2020 / 115794, application number 202080065146.8 entering the Chinese national phase, and invention name “Pancreatic endocrine progenitor cells and their uses”.
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS
[0003] This application claims priority to and the benefits of International Patent Application No. PCT / CN2019 / 106093, filed on September 17, 2019, the entire disclosure of which is incorporated herein by reference. Technical Field
[0004] The present invention relates to a culture medium and a method for producing pancreatic organoids in vitro. Background Art
[0005] The pancreas consists of three major cellular components: endocrine islets, exocrine acini, and ducts. The pancreatic β cells of the islets of Langerhans are the only cells that produce insulin in humans and almost all other vertebrates. In mice, islets are formed into spherical structures in which β cells form a core and are composed of α cells, δ cells, and pancreatic polypeptide (PP) cells. These cells produce insulin, glucagon, somatostatin, and pancreatic polypeptide (PP; Ppy), respectively (Pan and Wright, 2011). β cells have limited regenerative capacity, which is a susceptibility factor for the development of diabetes (Hardikar, 2016).
[0006] Cell therapy is considered a potential alternative to traditional treatments for diabetes. Islet and whole pancreas transplantation can restore glucose homeostasis by replenishing β cells (Lysy et al., 2013). Due to the limited availability of donors, attempts have been made to find strategies to generate β cells in vitro. In addition to using embryonic stem cell (ES) / induced pluripotent stem cell (iPSC)-based technologies to generate transplantable β cells (Cheng et al., 2012; Pagliuca et al., 2014; Rezania et al., 2014; Sneddon et al., 2012), organoids directly derived from tissues of interest have also been studied. However, it has proven difficult to generate new β cells from embryonic or adult pancreatic cultures, while closely related intestinal secretory cells are easily generated in such organoids (Gehart et al., 2019).
[0007] Mouse embryonic pancreatic progenitor cells cultured in three dimensions (3D) reflect exocrine and endocrine cell differentiation in vitro but do not support long-term expansion of pancreatic cells (Greggio et al., 2013; Sugiyama et al., 2013). Tissue culture strategies using adult ductal (Bonner-Weir et al., 2000; Gao et al., 2005; Huch et al., 2013; Jin et al., 2013; Ramiya et al., 2000; Rovira et al., 2010; Yatoh et al., 2007), acinar (Minami et al., 2005), and low-insulinemic (Seaberg et al., 2004; Smukler et al., 2011) cells are only marginally effective in expanding and differentiating putative progenitors into β-like cells.
[0008] Therefore, there is a need for methods and compositions for the in vitro production and long-term expansion of β cells. Summary of the invention
[0009] In one aspect, the present invention provides a method for producing pancreatic organoids in vitro, the method comprising: providing endocrine progenitor cells; and culturing the endocrine progenitor cells in vitro in an organoid culture medium in 3D under conditions suitable for producing pancreatic organoids containing functional β cells and / or β-like cells, preferably, the organoid culture medium further comprises a three-dimensional matrix, such as Matrigel. TM and hydrogels.
[0010] In some embodiments, the endocrine progenitor cells can be separated from adult pancreatic islet cells. In some embodiments, the endocrine progenitor cells are provided in an adult pancreatic islet cell population (e.g., without separation). In some factual schemes, the endocrine progenitor cell population can be provided in a substantially pure and isolated form, or in a form of co-enrichment with other adult pancreatic islet cells, or in a form naturally present in adult pancreatic islet cells obtained from a subject.
[0011] In some embodiments, the adult pancreatic islet cells may be from humans, and the endocrine progenitor cells may be MSLN +. The endocrine progenitor cells may also express one or more of UPK1B, S100A6, LGALS4, SDCBP2, SDC1, IGFBP3, HMGA1, ITGB4, ITGB6, HN1, GPRC5A, SLPI, LAMC2, FERMT1, MGLL, SEMA3B, TST, SFN, CDH3 and PROCR. In some embodiments, the method further comprises: contacting the isolated adult human islet cells with an anti-MSLN antibody or an antigen-binding fragment thereof in vitro, followed by fluorescence-assisted cell sorting (FACS) to isolate the endocrine progenitor cells. In certain embodiments, the organoid culture medium for culturing human cells may include a basal culture medium such as DMEM / F12 supplemented with one or more of the following: 10-200 (e.g., 50) ng ml -1 EGF, 1-50 (e.g., 10) ng ml -1 FGF2, 1-10 (e.g., 3) μM Wnt agonist such as CHIR99021 or 1-100 (e.g., 30) ng / ml Wnt surrogate such as NGS (Next Generation Surrogate), 0.1-5 (e.g., 0.5) μM TGF-beta pathway inhibitor such as SB431542 or A83-01, 10-500 (e.g., 100) ng ml -1 Bmp inhibitors such as Noggin, 1-10 (e.g., 2.5) μM Rock inhibitors such as Y27632, and 1-10 (e.g., 0.5) μM p38 inhibitor SB202190; wherein, optionally, the basal medium is also supplemented with one or more of the following: 1-5% (e.g., 2%) B27, 0.1-5% (e.g., 1%) ITS, 0.1-5 (e.g., 2) μg ml -1 Heparin and 1-100 (e.g., 50) ng ml -1 VEGFa.
[0012] In some embodiments, the adult pancreatic islet cells can be from mice, and the endocrine progenitor cells can be Procr +. In some embodiments, the endocrine progenitor cells may also express one or more of Rspo1, Fgf1, Upk3B, Hoxa5 and Msln. In some embodiments, the 3D culture step may also include co-culturing with multiple endothelial cells. In some embodiments, the method further includes contacting isolated adult mouse islet cells with an anti-Procr antibody or an antigen-binding fragment thereof in vitro, followed by fluorescence-assisted cell sorting (FACS) to isolate endocrine progenitor cells. In some embodiments, the culture medium for mouse cells may include a basal medium such as DMEM / F12, supplemented with one or more of the following: 10-200 (e.g., 50) ng ml -1 EGF, 1-50 (e.g., 10) ng ml -1 FGF2 and 1-20 (e.g., 5) ng ml -1 VEGFa; Optionally, the basal medium further comprises one or more of the following: 1-5% (e.g., 2%) B27, 0.1-5% (e.g., 1%) ITS, and 0.1-5 (e.g., 2) μg ml -1 heparin.
[0013] In some embodiments, the 3D culturing or co-culturing step may include culturing until the endocrine progenitor cells form colonies with a diameter of about 100-300 μm, and continuing to culture the colonies to form pancreatic organoids with a diameter of about 150-500 μm.
[0014] In another aspect, the present invention provides a method for obtaining pancreatic organoids in vitro, the method comprising: (a) enriching endocrine cells from an adult pancreas, preferably, the enrichment is performed by one or more of the following methods: (1) staining isolated adult pancreatic cells with TSQ (6-methoxy-8-toluenesulfonamide-quinoline) followed by FACS; (2) density gradient centrifugation to separate adult pancreatic cells; and (3) manually picking and isolating islets from an adult pancreas; and (b) 3D culturing the enriched endocrine cells in an organoid culture medium under conditions suitable for producing functional β cells and / or β-like cells, preferably, the organoid culture medium also includes a three-dimensional matrix.
[0015] In some embodiments, the organoid culture medium may include Matrigel TM or hydrogel and a basal medium such as DMEM / F12 supplemented with one or more of the following: 10-200 (e.g., 50) ng ml -1 EGF, 1-50 (e.g., 10) ng ml -1FGF2, 1-10 (e.g., 3) μM Wnt agonist such as CHIR99021 or 1-100 (e.g., 30) ng / ml Wnt surrogate such as NGS (Next Generation Surrogate), 0.1-5 (e.g., 0.5) μM TGF-beta pathway inhibitor such as SB431542 or A83-01, 10-500 (e.g., 100) ng ml -1 Bmp inhibitors such as Noggin, 1-10 (e.g., 2.5) μM Rock inhibitors such as Y27632, and 1-10 (e.g., 0.5) μM p38 inhibitor SB202190; in some embodiments, the basal medium can be supplemented with one or more of the following: 1-5% (e.g., 2%) B27, 0.1-5% (e.g., 1%) ITS, 0.1-5 (e.g., 2) μg ml -1 Heparin and 1-100 (e.g., 50) ng ml -1 VEGFa. In some embodiments, the pancreatic organoid has a diameter of about 50-500 or about 100-300 μm.
[0016] In various embodiments, any of the methods disclosed herein further comprises: expanding the pancreatic organoid by at least 10, at least 20, or at least 30 passages. The method may further comprise culturing the expanded pancreatic organoid for about 1-12 or 1-4 or 2-12 weeks (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 weeks or longer, or about 7-100 days) to produce mature organoids. In some embodiments, the mature organoid can detect glucose and produce and secrete insulin in response to glucose.
[0017] The present invention also provides a method for obtaining endocrine cells, the method comprising: contacting adult pancreatic islet cells with an anti-MSLN antibody or an antigen-binding fragment thereof in vitro; and isolating MSLN bound to the anti-MSLN antibody or its fragment. + Endocrine progenitor cells are preferably sorted using fluorescence assisted cell sorting (FACS).
[0018] The present invention also provides a method for obtaining endocrine progenitor cells, the method comprising: contacting adult pancreatic islet cells with an anti-Procr antibody or an antigen-binding fragment thereof in vitro; and isolating the Procr bound to the anti-Procr antibody or the fragment thereof. + Endocrine progenitor cells, preferably, said isolating uses fluorescence assisted cell sorting (FACS).
[0019] The present invention also provides a composition comprising a plurality of endocrine progenitor cells isolated from adult pancreatic islet cells, a culture medium and optionally a plurality of endothelial cells. In some embodiments, the endocrine progenitor cells express Procr. In some embodiments, the culture medium further comprises a three-dimensional matrix, preferably Matrigel. TM or hydrogel.
[0020] In some embodiments, the adult pancreatic islet cells are human, and the endocrine progenitor cells express MSLN and optionally also express UPK1B, S100A6, LGALS4, SDCBP2, SDC1, IGFBP3, HMGA1, ITGB4, ITGB6, HN1, GPRC5A, SLPI, LAMC2, FERMT1, MGLL, SEMA3B, TST, SFN, CDH3 and PROCR. One or more. In some embodiments, the culture medium for human cells includes a basal medium such as DMEM / F12, and the basal medium is supplemented with one or more of the following: 10-200 (e.g., 50) ng ml -1 EGF, 1-50 (e.g., 10) ng ml -1 FGF2, 1-10 (e.g., 3) μM Wnt agonist such as CHIR99021 or 1-100 (e.g., 30) ng / ml Wnt surrogate such as NGS (Next Generation Surrogate), 0.1-5 (e.g., 0.5) μM TGF-beta pathway inhibitor such as SB431542 or A83-01, 10-500 (e.g., 100) ng ml -1 Bmp inhibitors such as Noggin, 1-10 (e.g., 2.5) μM Rock inhibitors such as Y27632, and 1-10 (e.g., 0.5) μM p38 inhibitor SB202190; wherein, optionally, the basal medium is also supplemented with one or more of 1-5% (e.g., 2%) B27, 0.1-5% (e.g., 1%) ITS, 0.1-5 (e.g., 2) μg ml -1 Heparin and 1-100 (e.g., 50) ng ml -1 VEGFa.
[0021] In some embodiments, the adult pancreatic islet cells are of mouse origin, and the endocrine progenitor cells express Procr and optionally also express one or more of Rspo1, Fgf1, Upk3B, Hoxa5 and Msln. In some embodiments, the culture medium for mouse cells includes a basal medium such as DMEM / F12, and the basal medium is supplemented with one or more of the following: 10-200 (e.g., 50) ng ml -1 EGF, 1-50 (e.g., 10) ng ml-1 FGF2 and 1-20 (e.g., 5) ng ml -1 VEGFa; optionally, the basal medium further comprises 1-5% (eg, 2%) B27, 0.1-5% (eg, 1%) ITS, and 0.1-5 (eg, 2) μg ml -1 One or more of heparin.
[0022] Another aspect of the present invention is also directed to a pancreatic organoid comprising functional β cells and / or β-like cells differentiated in vitro from endocrine progenitor cells, wherein the endocrine progenitor cells are isolated from adult pancreatic islet cells. In some embodiments, the pancreatic organoid can detect glucose and produce and secrete insulin in response to glucose. In some embodiments, the pancreatic organoid has a diameter of about 50-500 or about 100-300 μm.
[0023] Another aspect of the present invention also relates to the culture medium disclosed herein, which is used for the in vitro expansion and / or differentiation of pancreatic progenitor cells and pancreatic organoids.
[0024] The present invention also provides the use of the organoid as described herein for treating or preventing diabetes, or for in vitro screening of agents for treating or preventing diabetes. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Figure 1A -1M indicates that single-cell RNA sequencing analysis revealed a novel pancreatic cell population with EMT properties. Figure 1A Graphs depicting the distribution of the number of unique molecular identifiers (UMIs) per cell (left) and the number of genes detected per cell (right) for pancreatic single-cell (sc) RNA-Seq data. Figure 1B The dot plots are for reproducibility between three biological replicates. The average gene expression values (Log2(TPM+1)) of all cells from three single-cell RNA sequencing experiments were used for calculation (r=Pearson correlation coefficient). Figure 1C t-SNE plots of three independent single-cell RNA sequencing experiments. The cell counts and indicated cell types for each experiment are marked in parentheses. Throughout the figures, unless otherwise stated, “Mesen” indicates mesenchyme, “Endo.” indicates endothelium, and “New pop” indicates new population. Figure 1D A series of t-SNE plots of the expression of marker genes for endocrine or exocrine cells. Figure 1D , 1E and 1I, post hoc cluster annotation is based on the expression of known cell type markers; and different clusters represent the same cell type, e.g. Figure 1C shown. Figure 1EA series of t-SNE plots of marker gene expression for cell lineages other than endocrine and exocrine. Figure 1F t-SNE plot of 7160 pancreatic single-cell (sc) RNA-sequencing profiles (dots) and post hoc annotations. New populations (new pop.) are indicated. Cell counts of designated cell types are in parentheses. Cells were pooled from three biological replicates. Figure 1G is a series of tSNE plots and accompanying Vlin plots illustrating gene expression in different pancreatic cell types. Figure 1F Indicates that different clusters represent the same cell type. Figure 1H is a series of tSNE plots and accompanying Vlin plots illustrating gene expression in different pancreatic cell types. Different clusters represent the same cell type, e.g. Figure 1F shown. Fig. 1I t-SNE plot of marker gene expression for new cell populations. Figure 1J It is a heat map of cell type enriched genes. Each column represents a cell and each row represents a signature gene. The shading ranges from dark shading to lighter shading, representing the relative gene expression levels from low to high, respectively. Figure 1K Dot plot of the characteristic genes for each cluster. The shading indicates the mean expression level and the size of the dot indicates the fractional expression. Figure 1L For the up-regulated genes in the new group (1536 genes were selected, p value 5x10 -3 ) of selected Gene Ontology (GO) terms. Figure 1M Included are tSNE plots and Vlin plots, illustrating that the expression levels of epithelial and mesenchymal markers are projected onto the t-SNE plot. The Vlin plot below the t-SNE plot shows the expression levels (Log2(TPM+1)) of the indicated genes in each cell type. The (circled) new population expresses epithelial and mesenchymal markers, indicating EMT characteristics.
[0026] Figure 2A-2I indicating that new populations in adult islets are consistent with embryonic endocrine cell subpopulations. Figure 2A tSNE plots showing two different single-cell RNAseq datasets containing endocrine precursors expressing E14.5Ngn3 that are currently publicly available for single-cell RNA sequencing datasets of adults and posthoc annotations. Shown as aligned (left) and split (right) plots. Cell counts and new populations (new pop.) for each dataset are shown in parentheses. Figure 2B To show the tSNE plots of pancreatic endocrine and exocrine marker gene expression levels for each indicated cell type, the color bar and Log2(TPM+1) value for each indicated gene are shown. Figure 2Ct-SNE plots of epithelial and mesenchymal marker expression levels for endocrine precursors expressing E14.5 Ngn3. Color bars and Log2(TPM+1) values for each indicated gene are shown. Similar to adult new cell populations, the (circled) new subpopulations of endocrine precursors expressing E14.5 Ngn3 express epithelial and mesenchymal markers, indicating EMT characteristics. Figure 2D t-SNE plot showing the expression level of Ngn3. Figure 2E t-SNE plot showing the expression of Rspo1 and Procr in the new population. The color bar and Log2(TPM+1) value of each indicated gene are shown. E14.5 Ngn3 + The expression levels of Rspo1 and Procr in the new population cells (circled) and adult new population cells are consistent, while the expression of Ngn3 is absent in adult new population cells. Figure 2F Dot plots are shown showing the expression signatures of the new cell populations in the three datasets. Figure 2G t-SNE plot showing the expression levels of marker genes in the new cell population. Three datasets are shown separately for comparison. The color bar and Log2(TPM+1) value of each indicated gene are shown. In each dataset, cells are divided into the new cell population and others. The shading indicates the average expression level and the size of the point indicates the fractional expression. Figure 2H Graphs showing the developmental trajectories of adult new cell populations generated by Monocle2 and α, β, δ, and PP cells (4,986 cells used). Colors in the left panel indicate cell type, cell counts of designated cell types are marked in parentheses, and pseudo-time (arbitrary units) is depicted from dark blue to light blue (right panel). Fig.2I Gene branch heatmap depicting gene expression along each branch in pseudotime. An independent expression pattern is calculated over the entire pseudotime trajectory of each branch. Therefore, the portion of the trajectory before the branch point is shown separately for each branch. Genes are clustered based on their expression patterns across pseudotime, and selected genes with differential expression along the branches are marked on the right.
[0027] Figures 3A-3L Characterization of isolated novel islet populations using Procr surface marker. Figure 3A Figure 3. Gating strategy for FACS analysis of Procr-expressing cells in unstained control islets. Doublets were excluded based on forward scatter and trigger pulse width. CD31, CD45, and Ter119 antibody labeling excluded Lin + Cell. Proc + EpCAM + The analysis was performed in pancreatic islet epithelial cells. Figure 3BFigure 3. Gating strategy for FACS analysis of samples labeled with antibodies for pancreatic procr-expressing cells. Doublets were excluded based on forward scatter and trigger pulse width. CD31, CD45, and Ter119 antibody labeling excluded Lin + Cell. Proc + EpCAM + The analysis was performed in pancreatic islet epithelial cells. Figure 3A and Figure 3B In , one of three biological replicates is shown. Figure 3C Figure 1 is a summary of FACS analysis of cells expressing Procr in manually selected mouse islets. Lin (including CD31, CD45 and Ter119) and EpCAM antibody staining were performed. + and non-epithelial cells are excluded. - EpCAM + 1.02 ± 0.14% of cells in the pancreatic epithelial compartment are Procr + The data were obtained from five biological replicates and are presented as mean ± sem. Figure 3D For each isolated cell population (i.e., FACS-sorted islets or non-islet Procr + and Procr - Figure 2 shows the expression level of new population signature genes in pancreatic cells. + Cells are enriched for the novel population, with high levels of novel population marker expression. n=3 biological replicates. For each replicate, cells were isolated from four mice. Data are presented as mean ± sem. Figure 3E Ngn3 - Procr in Cre and Rosa26-tdTomato islets + FACS analysis of cells. - , EpCAM + Mark. Most of the Procr + Cells are tdTomato + (tdTom + ). One of three similar biological replicates is shown. Figure 3F Diagram of a dual reporter allele of Procr with a membrane GFP (mGFP)-2A-LacZ cassette inserted after the ATG start codon of Procr. Figure 3G Diagram of the targeting strategy for generating ProcrmGFP-2A-LacZ knock-in dual reporter mice. The design of Southern blot probes and genotyping primers are shown in the figure. Figure 3HIncluded are: Southern blot analysis images of BamHI-digested DNA from mouse embryonic stem cells using a 5' external probe, showing an 8.5kb band in addition to the 9.9kb WT band (left); and Southern blot analysis images of SacI-digested DNA from mouse embryonic stem cells using a 3' external probe, showing a 5.6kb band in addition to the 6.9kb WT band (right) in clones where homologous recombination occurred at the Procr locus. Fig. 3I This is a gel image of the genotyping PCR reaction products, and the image shows that lanes #2, 3, 5, and 7 are heterozygous. The image shows one of three similar experiments. Figure 3J This is an image of whole mount X-gal staining showing the expression of individual LacZ in ProcrmGFP-2A-LacZ islets (Procr + ) cells. Wild-type negative control is shown on the right. Scale bar is 20 μm. Similar distribution patterns were observed in three mice. Figure 3K For Proc + and Procr - FACS analysis of cells (images) and instructions Procr + Cells and mGFP + Overlay of cells demonstrating the validation of the ProcrmGFP-2A-LacZ knock-in reporter mouse. + or Procr - Cells were sorted by FACS and verified by mGFP immunostaining. + and mGFP + Overlapping quantification of cells. ProcrmGFP-2A-LacZ knock-in mice recapitulate Procr expression in islets. n=3 biological replicates. Data are presented as mean ± sem. Scale bar, 20 μm. Figure 3L Representative confocal images of whole mount immunostaining of ProcrmGFP-2A-LacZ islets, showing that mGFP+ cells (Procr + cells, arrows) do not interact with mature β cells (Ins + ), α cells (Gcg + ),δ-cells(Sst + ) or PP cells (Ppy + ) Overlay. Scale bar, 20 μm. Similar results were confirmed in n=3 mice. Figure 3M Representative confocal images of pancreatic sections immunostained for mGFP + Cells (Procr +Cells, arrows) express the epithelial marker EpCAM and the mesenchymal marker Col1a1. Scale bar, 20 μm. Sections from n=3 mice were stained and analyzed.
[0028] Figure 4A and 4B Pancreatic organoids cultured for 7 and 28 days. Figure 4A Bright field images of freshly isolated primary islet cells after 7 days of culture. + or Procr - Islet cells were isolated from ICR mice and cultured separately. + Cells form colonies. Experiments were performed with n=3 biological replicates. For each replicate, cells were sorted from at least 5 mice. Scale bar 50 μm. Figure 4B is a scatter plot showing the size of each islet organoid cultured for 7 or 28 days, with or without endothelial cells. The experiment was performed with 3 biological replicates. One of three similar results is shown. Average size is shown as mean ± sem. Figures 5A-5N Proof from a single Proc + Pancreatic islet organoids derived from islet progenitor cells can express insulin. Figure 5A The sorted (from ICR or FVB mice) and CD31 + Procr from endothelial cells (from actin-DsRed) co-culture + and Procr - FACS analysis of cells. FACS analysis of Procr). Bright field / fluorescence representative images show freshly isolated primary islet cells after 5 or 8 days in culture. Red fluorescence indicates CD31 + Under these culture conditions, only Procr + Cells will form islet organoids. n = 5 biological replicates. For each replicate, cells were sorted from at least 5 mice. Scale bar 50 μm. Figure 5B For the 28-day culture of Procr + Bright field (left) and whole mount immunofluorescence images (right) of cell-derived pancreatic islet organoids. + Cells and CD31 + Endothelial cells were sorted from ICR mice. Endothelial cells were stained with red CD31 antibody. n = 3 biological replicates. For each replicate, cells were sorted from at least 5 mice. "Org." indicates organoid. Scale bar is 50 μm. Figure 5C is a scatter plot showing the size of each islet organoid cultured for 7 or 28 days. n = 3 biological replicates, showing one of three similar results. Average organoid size is presented as mean ± sem. Figure 5D Included are representative confocal images of whole-mount insulin immunostaining in fresh islets or organoids at 7 or 28 days in culture, with and without glucose challenge. Scale bar represents 20 μm. “hi glucose” indicates high glucose. Figure 5E Scatter plots showing insulin per organoid under each indicated condition + Percentage of (highly expressing) cells. n = 3 biological replicates, one of three similar results is shown. Average percentages are expressed as mean ± sem. "d7" means day 7; "hi glu" means high glucose. Fig. 5F Included are graphs showing expression levels of β-cell marker genes detected by qPCR under each indicated condition. n=3 biological replicates. Data are expressed as (mean+minimum) / maximum. Figure 5G For representative population measurements of dynamically normalized Fluo-4 fluorescence intensity, the graph shows primary day 28 islet organoids sequentially challenged with 2, 20, 2, 20, 2, and 20 mM glucose and 30 mM KCl. The x-axis represents time. n=3 biological replicates are shown in each graph. Figure 5H Included are electron microscopy images and quantification of intracellular granules in sections for each indicated culture condition (e). Fresh pancreatic β-cell samples are shown. An increasing number of crystalline insulin granules were found in organoids at day 28 after glucose challenge, indicating β-cell maturation. n = 3 biological replicates. One of three similar quantitative results is shown. Scale bar represents 1 μm. “D7” indicates day 7; “D28” indicates day 28; “Hi glu.” indicates high glucose; “Org.” indicates organoid. Fig.5I yes Figure 5H Scatter plot quantifying the results observed in .
[0029] Figure 5J Schematic diagram of ELISA measurement of insulin secretion from islet organoids on day 28 challenged with 2, 20, 2, 20, 2, and 20 mM glucose, incubated for 30 min per condition. n=3 biological replicates. Data are presented as mean ± sem. Figure 5K Included are whole mount immunostaining images of the α-cell marker Gcg, the δ-cell marker Sst, or the PP-cell marker Ppy expressed by cells in fresh islets. Figure 5L yes Figure 5K Quantitative plot of the results observed in . Figure 5K Included are whole mount immunostaining images of the α-cell marker Gcg, δ-cell marker Sst, or PP-cell marker Ppy expressed by cells in day 28 organoids. Figure 5N yes Figure 5MA quantitative plot of the results observed in Figure 5K-5N , based on n = 3 biological replicates to validate the presence of different types of hormone-expressing cells within organoids. One of three similar quantifications is shown. n = 3 mice were used for quantification of fresh islets. Scale bar represents 20 μm. Data are expressed as mean ± sem.
[0030] Figure 6A-6N Procr + Cell-derived organoids can be expanded in vitro. Fig. 6A Representative images of cultured organoids from different passages are included. All passage experiments were performed for n=3 biological replicates. Scale bar is 50 μm. Figure 6B for Fig. 6A Schematic representation of the size of cultured organoids. One of three similar quantifications is shown. The average size of the organoids is shown as mean ± sem. Figure 6C Islet organoids (derived from primary mouse pancreatic islets Procr + Expansion curves of 104 cells from passage 1 to passage 20. n = 3 biological replicates. Data are presented as mean ± sem. Fig.6D Schematic diagram of the organoid expansion / maturation model. Fig. 6E Representative images of whole mount immunostaining for β-cell marker Ins, α-cell marker glucagon (Gcg), δ-cell marker somatostatin (Sst), and PP-cell marker pancreatic polypeptide (Ppy) in organoids at passage 15, day 30 after glucose challenge. Scale bar, 20 μm. Fig. 6F for Fig. 6E Quantification of whole mount immunostaining in . n = 3 biological replicates. One of three similar quantification results is shown. Average percentages are expressed as mean ± sem. Figure 6G Representative images of whole mount immunostaining for the β cell marker Ins, α cell marker glucagon (Gcg), δ cell marker somatostatin (Sst), and PP cell marker pancreatic polypeptide (Ppy) in organoids at passage 7, day 30 after glucose challenge. Scale bar, 20 μm. Figure 6H for Figure 6G Quantification of whole mount immunostaining in . n = 3 biological replicates. One of three similar quantification results is shown. Average percentages are expressed as mean ± sem. Fig.6I Representative population measurements of dynamic normalized Fluo-4 fluorescence intensity of islet organoids from passage 15 day 30 challenged sequentially with 2, 20, 2, 20, 2, and 20 mM glucose and 30 mM KCl. The x-axis represents time. n=3 biological replicates are shown separately. Figure 6JElectron microscopy images of intracellular granules including sections. Crystallized insulin granules were found in organoids at passage 15, day 30 after glucose challenge, indicating β-cell maturation. n = 3 biological replicates. Scale bar represents 1 μm. Figure 6K Figure 1 is an ELISA measurement of insulin secretion from islet organoids, which were day 30 islet organoids at passage 15 challenged with 2, 20, 2, 20, 2, and 20 mM glucose, incubated for 30 minutes at each concentration. n = 3 biological replicates. Data are presented as mean ± sem. Figure 6L Electron microscopy images of intracellular granules in sections. Crystallized insulin granules were found in organoids at day 7 and day 30 after glucose challenge. n = 3 biological replicates. Scale bar represents 1 μm. Figure 6M Graph of ELISA measurement of secreted insulin from islet organoids at passage 7, day 30, sequentially challenged with 2, 20, 2, 20, 2, and 20 mM glucose, each condition incubated for 30 minutes. n=3 biological replicates. Data are presented as mean ± sem. Figure 6N Representative population measurements of dynamic normalized Fluo-4 fluorescence intensity of islet organoids at passage 7, day 30, sequentially challenged with 2, 20, 2, 20, 2, and 20 mM glucose and 30 mM KCl. The x-axis represents time. n=3 biological replicates are shown separately.
[0031] Figures 7A-7N We demonstrated that long-term cultured organoids restored insulin-dependent glucose homeostasis in streptozotocin (STZ)-induced T1D mice. Fig. 7A is a graph showing blood glucose levels after transplantation. Immunodeficient mice were made diabetic with streptozotocin (STZ) 7 days before transplantation. Blood glucose levels were routinely checked for random feeding. After transplantation of 1,000 7th or 15th generation islet organoids, blood glucose dropped to normal levels, similar to controls transplanted with 300 islets in mice. Non-transplanted diabetics remained in a hyperglycemic state. Groups are represented by colored lines, and the number of mice measured in each group is marked in brackets. Data are expressed as mean ± sem. Figure 7B Figure 2 is a graph of mouse body weight after transplantation. Immunodeficient mice were made diabetic with streptozotocin (STZ) 7 days before transplantation. Body weight changes were checked regularly. Weight loss in diabetic patients could be rescued by transplantation of 1,000 islet organoids at passage 7 or 15, similar to controls transplanted with 300 islets. Weight loss continued in non-transplanted diabetic patients. Groups are represented by colored lines, and the number of mice measured in each group is marked in parentheses. Data are expressed as mean ± sem. Figure 7Cis a graph of a glucose tolerance test (GTT) administered 1 month after transplantation, which shows that glucose tolerance was significantly improved in the transplanted organoid and transplanted islet groups. Groups are represented by colored lines, and the number of mice analyzed in each group is marked in brackets. Data are expressed as mean ± sem. Fig.7D Figure 2 is a graph showing ELISA measurements of serum insulin in each designated group before and after glucose injection (15 minutes after glucose injection). The number of mice used in each group was Fig. 7A and 7C The data are presented as mean ± sem. Fig. 7E Representative images of immunofluorescence staining of β cell marker Ins, α cell marker Gcg, δ cell marker Sst, or PP cell marker Ppy in regenerated tissues 1 month after organoid transplantation. n = 3 mice. Scale bar, 20 μm. “Org.” indicates organoid. Figure 7F Quantification of cells expressing different hormones in regenerated tissues 1 month after organoid transplantation. n = 3 mice. Figure 7G Electron microscopy images of intracellular granules in sections. Organoid cells were isolated 1 month after transplantation. Crystallized insulin granules indicate β-cell maturation. n = 3 mice. Scale bar represents 1 μm. Figure 7H t-SNE2 plot of 2,129 transplanted hormone expression single-cell RNA sequencing profiles (dots). Organoid cells were isolated 1 month after transplantation. Data are displayed by alignment to the main single-cell RNA sequencing datasets described above and colored by cluster assignment and post hoc annotation (left), or by cell source (right). Transplanted cells were pooled from n=3 mice. Fig.7I Distribution plots showing the number of UMIs per cell (left) and the number of genes detected per cell (right) for transplanted single-cell (sc) RNA sequencing datasets. Figure 7J t-SNE plots of Sc RNA-seq profiles (dots) of transplanted or original samples in split view, colored by cluster assignment and annotated post hoc. Cell counts for the indicated samples and cell types are noted in parentheses. "Mesen." indicates mesenchyme; "Endo." indicates endothelium; "New pop." indicates new population. Figure 7K It is a heat map of endocrine cell type signature genes. Each column represents a cell and each row represents a signature gene. To compare similarities, transplanted or primary cells are shown separately. The shading from dark to light shades represents the relative gene expression levels from low to high, respectively. Figure 7L Included are Vlin plots showing comparable expression levels (Log2(TPM+1)) of alpha or beta cell marker genes between primary and transplanted cells. Figure 7MFigure 2 is a dot plot of genes characteristic of endocrine cell types. Transplanted or primary cells are shown for comparison. Shading indicates mean expression level and dot size indicates expression score. Figure 7N Included are Vlin graphs showing comparable expression levels of delta or PP cell markers between primary and transplanted cells (Log2(TPM+1)).
[0032] Fig. 8A and 8B ProcRNAs lacking endocrine marker expression were found in human pancreatic islets + cell. Fig. 8A Representative confocal images of endocrine hormones (shown in green) and PROCR (shown in red) staining on human pancreatic sections from the indicated donors. The islet outlines are circled. Similar to mouse, human islet Procr + Cells do not overlap with hormone expressing cells. Scale bar is 20 μm. 8B is a representative confocal image of PROCR (shown in red) staining on human pancreatic sections from the indicated donors. PROCR is also expressed in the exocrine compartment of the human pancreas. Scale bar is 20 μm.
[0033] Figures 9A-9C Isolation of human pancreatic islet single cells by FACS is demonstrated. Fig.9A Representative FACS profiles of TSQ staining in Hu0124 donor. Three different levels of TSQ staining were gated. Fig. 9B Representative confocal images of endocrine markers INS / GCG or exocrine markers AMY / KRT19 stained in each indicated cell population sorted from Hu0124 donors (shown in red). High TSQ cells are enriched for islet hormone expressing cells, while exocrine cells are TSQ-low or TSQ-neg. Scale bar is 20 μm. Fig. 9C FACS profiles of TSQ staining in different donors.
[0034] Figures 10A-10D Screening for factors that promote growth of human pancreatic islet organoids is described. Fig. 10A Representative brightfield images of organoids are annotated with graphs showing the number of organoids cultured from donor Hu1021 under each indicated condition and quantifying organoid size. Fig. 10B Representative brightfield images of organoids are annotated with graphs showing the number of organoids cultured from donor Hu1130 under each indicated condition and quantifying organoid size. Fig. 10C Schematic diagram for quantification of organoid size, annotated to show the number of organoids cultured from donor Hu0228 under each indicated condition. Figures 10A-10C The data are expressed as mean ± sem. Fig. 10DRepresentative confocal images of organoids from Hu1130 donors stained for the endocrine markers INS (shown in red) and GCG (shown in green). Fig. 10A , 10B Scale bars in 10D and 10D are 20 μm.
[0035] Figures 11A-11D represents the establishment of a 3D culture system to expand human pancreatic islet organoids. Fig.11A Graph showing the number of primary passage organoids formed per 10,000 high TSQ pancreatic cells from three different donors. Fig. 11B Representative brightfield images of islet organoids from Hu0228 donors, with culture days indicated in parentheses. Representative ductal organoids with prominent hollow structures are also shown for comparison. Scale bar 100 μm. Fig. 11C Size and growth curves of islet organoids (derived from primary Hu0408 donors) from passage 1 to passage 7. Data are presented as mean ± sem. Fig.11D Representative bright field images of pancreatic islet organoids (Org) cultured from Hu0408 donors at each indicated passage. Culture days are in brackets. Scale bar is 100 μm.
[0036] Figures 12A-12E These results suggest that human pancreatic islet organoids can express insulin, respond to glucose stimulation, and contain different endocrine cell types. Fig. 12A Representative confocal images of insulin staining in pancreatic islet organoids (Org) from donor Hu0228 at the indicated passages (culture days are in brackets). Fig. 12B Representative confocal images of insulin staining in pancreatic islet organoids (Org) from donor Hu0408 at the indicated passages (culture days in brackets). Fig. 12A and 12B As shown, insulin (INS) + β-like cells predominate in pancreatic islet organoids, and glucagon (GCG) + Alpha-like cells were present at a lower frequency. No SOX9 (ductal cell marker) expression was detected in islet organoids. Scale bar, 20 μm. Fig. 12C Representative confocal images of SOX9 staining in ductal organoids. Scale bar is 20 μm. Fig.12D Graph showing representative population measurements of dynamic normalized Fluo-4 fluorescence intensity of the first islet organoid (from a Hu0228 donor) sequentially challenged with 2, 20, 2, 20, 2, and 20 mM glucose. The x-axis represents time. Fig.12E Representative confocal images of INS staining in islet organoids from Hu0228 or Hu0408 donors at passage 3 and 6. Scale bar, 20 μm.
[0037] Figures 13A-13C Procr in organoids + The cells are highly proliferative. Fig.13A Representative confocal images of passage 3 and 6 pancreatic islet organoids from Hu0228 or Hu0408 donors stained for EdU. Scale bar, 20 μm. Fig. 13B The first pancreatic islet organoid culture from Hu0228 donor expressed Procr + FACS analysis of cell percentages. Fig. 13C Representative confocal images of EdU staining and sorting of islet organoids from the + EdU in PROCR- cells + Quantification of cell percentage. PROCR + The proliferation capacity of organoid cells is significantly higher than that of PROCR-organoid cells. Scale bar represents 20 μm.
[0038] Figures 14A-14F scRNA sequencing analysis revealed a potential population of islet progenitor cells in the adult pancreas. Figures 14A-14B (shown) t-SNE plots of 20,660 human and 7,051 mouse pancreatic single-cell (sc) RNA sequencing profiles (dots), colored by cluster assignment and annotated post hoc. Integrated ( Fig.14A ) and split( Fig. 14B ) view. The progenitor cell clusters are circled in cyan. The number of cells in each cluster is shown in ( Fig. 14B ) in parentheses. Cells were pooled from n = 3 biological replicates in mouse and 8 data sets in human. “quie.” indicates quiescent. “act.” indicates active. “endo.” indicates endothelial. ( Fig. 14C ) Individual gene t-SNE plots show the expression levels and distribution of representative marker genes for each cell type. Colors from gray to blue represent relative gene expression levels from low to high. ( Fig.14D )Heatmap of cell type enriched genes. Each column represents a cell and each row represents a signature gene. Colors from purple to yellow indicate relative gene expression levels from low to high. Marker genes for pancreatic islet progenitor cells are shown in the cyan box on the left. "Quiet." indicates dormant. ( Fig.14E ) Single gene Vlin plots showing the expression levels (Log2(TPM+1)) of representative islet progenitor cell marker genes across different cell clusters. ( Fig.14F ) Developmental trajectories of islet progenitors, α and β cells generated by Monocle 2. Colors in the upper panel indicate cell type. Pseudo-time (arbitrary units) is depicted from dark blue to light blue (bottom panel). Figures 15A-15F Indicates MSLN +Islet cells are adult pancreatic islet progenitor cells with organoid-forming capacity. Figures 15A-15B ) Immunofluorescence staining of MSLN-expressing cells in human pancreatic sections. The islet compartments are distinguished based on green insulin staining. The ductal area is framed based on the luminal structure. MSLN antibody staining is shown in red. + Cells are small subpopulations located within the pancreatic islets ( Fig.15A ). There are some MSLN outside the islets + cell( Fig. 15B ). Scale bar = 20 μm. (e.g. Fig. 15C (shown) FACS analysis of MSLN expressing cells in human pancreatic sections. Doublets were removed based on the trigger pulse width of the cells. In the TSQ+ islet epithelial compartment, approximately 4% of the cells were MSLN + In the TSQ-non-islet compartment, ~1% of cells are MSLN + . n = 2 human samples were analyzed. Antibody unstained samples are shown as controls for APC-Cy7. ( Figures 15D-15E ) Total TSQ-hi cells or TSQ-hi, MSLN + Cells or TSQ-hi, MSLN- cells were sorted by FACS and cultured into pancreatic islet organoids. Fig.15D Representative images of culture day 4 are shown. TSQ-hi, MSLN + cells had the highest organoid formation efficiency, 6.6-fold higher than total TSQ-hi cells, whereas MSLN- cells could barely form organoids ( Fig.15E ). Fig.15F ) FACS analysis of organoids on day 14 showed that most MSLN + Cells are PROCR + .
[0039] Figures 16A-16C It was shown that co-culture with endothelial cells can promote the growth of human pancreatic islet organoids in vitro. Fig.16A ) Time-lapse images of human pancreatic islet organoids derived from TSQ-hi islet cells (culture day 0 to day 10). Fig. 16B ) Time-lapse images of human islet organoids derived from co-culture of TSQ-hi islet cells and endothelial cells (EC, arrows) (culture day 0 to day 10). Representative images of day 10 organoids released from the gel are also shown. Fig. 16C Quantification of organoid size (shown) indicated that EC co-culture promoted organoid growth. ***P<0.001. DETAILED DESCRIPTION
[0040] The production of functional β cells in vitro has generally proven to be challenging. The present disclosure is based on the discovery of a new cell population expressing the protein C receptor (Procr) in adult mouse and human pancreatic islets. These Procr + The cells do not express differentiation markers and have characteristics of epithelial-mesenchymal transition (EMT). + Procr expression allows the isolation of these cells from pancreatic islets. + The cells can robustly form islet-like organoids when cultured with endothelial cells (EC) at clonal density, whereas human islet cells do not require ECs to form organoids. Exponential expansion can be maintained in vitro for long periods of time by serial passaging, and differentiation can be induced at any time point in culture. + Progenitor cell-derived differentiated islet organoids predominate, whereas α-, δ-, and pancreatic polypeptide (PP) cells appear at lower frequencies. + Progenitor cell-derived organoids are glucose-responsive and can secrete insulin. When transplanted into diabetic patients, the organoids can reverse the disease. The findings disclosed herein show that adult pancreatic islets contain Procr + Endocrine cell population.
[0041] definition
[0042] For convenience, specific terms used in the specification, examples and appended claims are collected here. Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by one of ordinary skill in the art to which this invention belongs.
[0043] The following references provide the skilled artisan with general definitions of many of the terms used in the present invention: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed. 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, 5th Ed., R. Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991). Unless otherwise indicated, the following terms used herein have the meanings given below.
[0044] Unless otherwise stated or obvious from the context, as used herein, the term "or" should be understood to be inclusive. Unless otherwise stated or obvious from the context, as used herein, the terms "a", "an" and "the" should be understood to be singular or plural.
[0045] Unless otherwise specified or clear from the context, the term "about" as used herein should be understood as a range normally allowed in the art, such as a standard deviation of the average within 2. About can be understood as within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the indicated value. Unless otherwise clearly indicated herein, all numerical values provided herein are modified by the term about.
[0046] "Procr" and "PROCR" are used interchangeably to refer to protein C receptor, "Procr" generally refers to the gene or mRNA, and "PROCR" refers to the protein product, unless otherwise indicated. It should be understood that these terms include the entire gene, cDNA sequence, the entire amino acid sequence, or any fragment or variant thereof.
[0047] As used herein, "antibody" is a protein consisting of one or more polypeptides comprising a binding domain that binds to a target epitope. The term antibody includes monoclonal antibodies, which include immunoglobulin heavy and light chain molecules, single heavy chain variable domain antibodies, and variants and derivatives thereof, including chimeric variants of monoclonal and single heavy chain variable domain antibodies. The binding domain is substantially encoded by an immunoglobulin gene or an immunoglobulin gene fragment, wherein the protein immunospecifically binds to an antigen. Recognized immunoglobulin genes include κ, λ, α, γ, δ, ε, and μ constant region genes, as well as a large number of immunoglobulin variable region genes. Light chains are classified as κ or λ. Heavy chains are classified as γ, μ, α, δ, or ε, which in turn determine the immunoglobulin class, which is IgG, IgM, IgA, IgD, and IgE, respectively. For most vertebrate organisms, including humans and mice, the typical immunoglobulin structural unit comprises a tetramer composed of two identical pairs of polypeptide chains, each pair having one "light chain" (about 25 kD) and one "heavy chain" (about 50-70 kD). L ” and “V H ” refer to the variable domains of these light and heavy chains, respectively. “C L ” and “C H "" refer to the constant domains of these light and heavy chains, respectively." L and V H The three beta-chain loops on each chain are responsible for binding to the antigen and are called the "complementarity determining regions" or "CDRs". The "Fab" (antigen binding fragment) region includes a constant region and a variable region, V, from each heavy and light chain of the antibody.L ,C L ,V H and C H 1.
[0048] Antibodies include intact immunoglobulins and antigen-binding fragments thereof. The term "antigen-binding fragment" refers to an antibody polypeptide fragment that binds to an antigen or competes with an intact antibody (i.e., an intact antibody from which it is derived) for antigen binding (i.e., specific binding). Antigen-binding fragments can be produced by recombinant or biochemical methods well known in the art. Exemplary antigen-binding fragments include Fv, Fab, Fab', (Fab')2, CDR, paratope, and single-chain Fv antibodies (scFv), wherein V H and V L The chains are joined together (directly or through peptide linkers) to form a continuous polypeptide.
[0049] Another type of antibody called heavy chain antibody (HCA, also called two-chain or two-chain heavy chain antibody) has been reported in camelids, such as dromedary camels, Bactrian camels, wild Bactrian camels, llamas, alpacas, llamas, and guanacos (Hamers-Casterman et al., Nature, 363, 446-448 (1993); Wesolowski et al., Med. Microbiol. Immunol (2009) 198: 157-174; see also U.S. Patent No. 5,759,808; U.S. Patent No. 5,800,988; U.S. Patent No. 5,840,526 and U.S. Patent No. 5,874,541). Compared with conventional IgG-type four-chain immunoglobulins also produced by camelids, these antibodies lack the light chains and CH1 domains of conventional immunoglobulins, and their variable domains are sometimes referred to as "V H H". V H H can include four framework regions or "FRs", FR1, FR2, FR3 and FR4. The framework regions are interrupted by three CDRs, CDR1, CDR2 and CDR3. One of the notable features of these naturally occurring heavy chain antibodies is that Glu, Arg and Gly are mainly present in their V H The VL interface positions 44, 45 and 47 (Kabat numbering) of the H of the four-chain antibody are almost completely occupied by Gly, Leu and Trp in the conventional four-chain antibody VH. Compared with the relative insolubility of the VH domain of the traditional four-chain antibody, these differences are believed to be due to the relative insolubility of the camel HCA variable domain (V H H) due to its high solubility and stability. HTwo other notable features of the H domain are their relatively long CDR3 and the high incidence of cysteine pairs in the CDRs. It seems that cysteine pairs mediate the formation of disulfide bonds and are therefore involved in regulating the surface topology of the antibody binding site. In the crystal structure of the camel sdAb-lysozyme complex, a rigid loop that protrudes from the sdAb and is partially stabilized by the CDR disulfide bonds extends out of the binding site and into the lysozyme active site (Desmyter et al., Nature Struct. Biol., 3, 803-811 (1996)).
[0050] Antibodies also include variants, chimeric antibodies and humanized antibodies. As used herein, the term "antibody variant" refers to an antibody with a single or multiple mutations in a heavy chain and / or light chain. In some embodiments, the mutation is present in the variable region. In some embodiments, the mutation is present in the constant region. "Chimeric antibody" refers to an antibody in which a portion of the amino acid sequence of each of the heavy and light chains is homologous to the corresponding sequence in an antibody derived from a particular species or belonging to a particular class, and the remaining segments of the chain are homologous to the corresponding sequences of other species or classes. Typically, in these chimeric antibodies, the variable regions of the light and heavy chains mimic the variable regions of antibodies derived from a mammal, while the constant portion is homologous to the sequence in an antibody derived from another mammal. A significant advantage of these chimeric forms is that, for example, variable regions can be conveniently derived from currently known sequences using readily available hybridomas or B cells from non-human host organisms, and constant regions are derived from, for example, human cell preparations. Although the variable region has the advantage of being easy to prepare and specific without being affected by its source, when the antibody is injected, the constant region is human, which is less likely to induce an immune response in human subjects than the constant region of non-human origin. However, the definition is not limited to this particular example. "Humanized" antibody refers to a molecule with an antigen binding site of an immunoglobulin that is substantially derived from a non-human species, and the remaining immunoglobulin structure of the molecule is based on the structure and / or sequence of a human immunoglobulin. The antigen binding site may include a complete variable region fused to a constant region or a complementary determining region (CDR) of a suitable framework region that is only transplanted into the variable region. The antigen binding site may be wild type or modified by one or more amino acid substitutions, such as being modified to be more similar to human immunoglobulin. Some forms of humanized antibodies retain all CDR sequences (e.g., humanized mouse antibodies, which include all six CDRs from mouse antibodies). Other forms of humanized antibodies have one or more CDRs (one, two, three, four, five or six) that are changed relative to the original antibody, which are also referred to as "derived from" one or more CDRs of one or more CDRs.
[0051] An "anti-PROCR antibody" is an antibody that immunospecifically binds PROCR (e.g., an extracellular domain thereof). The antibody may be an isolated antibody. Such binding to PROCR exhibits a K of, for example, no greater than 1 μM, no greater than 100 nM, or no greater than 50 nM. d K can be determined by any method known to those skilled in the art. d , such as surface plasmon resonance experiments or cell binding experiments. The anti-PROCR antibody can be a monoclonal llama antibody, such as GS5, GS4, GS2, HD13, HD21, HD44, HD58 or HD61 disclosed in PCT / CN2017 / 115198, or an antigen-binding fragment thereof. Exemplary anti-PROCR antibodies inhibit the binding of PROCR to protein C. The anti-PROCR antibody can also be an "RCR-252" antibody, which refers to a monoclonal antibody with clone number RCR-252, as first described by Ye et al. in "Endothelial cell protein C receptor (EPCR) is the main receptor for protein C activation on arterial, venous and capillary endothelial cells," Biochem Biophys Res Commun 1999, 259: 671. RCR-252 is a rat anti-human PROCR antibody commercially available from a variety of sources, such as Abcam's product number ab81712 and Sigma's product number E6280. In some embodiments, the anti-PROCR antibody may be those disclosed in US20190045758 or PCT / CN2017 / 115198, which are incorporated herein by reference in their entirety. Other commercially available anti-PROCR antibodies may also be used, including those disclosed herein.
[0052] As used herein, the term "adult cell" refers to cells found throughout the body following embryonic development.
[0053] The term "pancreas" refers to a glandular organ that secretes digestive enzymes and hormones. In humans, the pancreas is a yellowish organ that is about 7 inches (17.8 cm) long and 1.5 inches (3.8 cm) wide. It lies below the stomach and connects to the small intestine, a muscular, hose-like portion of the gastrointestinal tract that extends from the lower end of the stomach (the pylorus) to the anal opening. Most of the pancreatic tissue consists of grape-shaped clusters of cells that produce a clear fluid (pancreatic juice) that flows through the common duct into the duodenum along with bile from the liver. Pancreatic juice contains three digestive enzymes: tryptase, amylase, and lipase, which, along with intestinal enzymes, complete the digestion of proteins, carbohydrates, and fats, respectively. Dispersed among the enzyme-producing cells of the pancreas are small groups of endocrine cells, called the islets of Langerhans, which secrete two hormones: insulin and glucagon. The islets contain several types of cells: alpha cells, which produce the hormone glucagon; beta cells (also referred to herein as "pancreatic beta cells"), which make the hormone insulin; and delta cells, which produce the regulator somatostatin. These hormones are secreted directly into the blood, and together they regulate the level of glucose in the blood. Insulin lowers blood sugar levels and increases the amount of glycogen (stored carbohydrates) in the liver; glucagon has the opposite effect. Failure of insulin-secreting cells to function properly can lead to diabetes mellitus (DM).
[0054] The terms "progenitor cell" and "precursor" cell are used interchangeably herein and refer to cells that have a more primitive cell phenotype (i.e., an earlier step in a developmental pathway or progression) than fully differentiated cells, which are cells produced by differentiation. Typically, progenitor cells also have a significant or very high proliferation potential. Depending on the developmental pathway and the environment in which the cells develop and differentiate, progenitor cells can produce a variety of different differentiated cell types or a single differentiated cell type.
[0055] The terms "pancreatic endocrine progenitor cells" and "endocrine progenitor cells" are used interchangeably herein and refer to progenitor cells that are capable of becoming pancreatic hormone-expressing cells or capable of forming pancreatic endocrine cells. In some embodiments, such progenitor cells are isolated from adult pancreatic islets and are Procr + , i.e., express Procr mRNA and / or protein. In some embodiments, such progenitor cells are MSLN + , that is, expressing MSLN mRNA and / or protein.
[0056] As described herein, the term "insulin-producing cells" refers to cells differentiated from pancreatic endocrine progenitor cells or their precursors that secrete insulin. Cells that produce insulin include the term pancreatic β cells as described herein, as well as β-like cells (i.e., insulin-positive, endocrine cells) that synthesize (i.e., transcribe insulin genes, translate proinsulin mRNA, and modify proinsulin mRNA into insulin protein), express (i.e., exhibit phenotypic characteristics carried by insulin genes), or secrete (release insulin into the extracellular space) insulin in a constitutive or inducible manner. For example, the insulin-producing cell population produced by differentiating insulin-positive endocrine cells or their precursors into β cells according to the method of the present invention can be pancreatic β cells or β-like cells having (e.g., at least one or at least two) characteristics of endogenous β cells and exhibiting GSIS reactions similar to endogenous adult β cells. The novelty of the compositions and methods of the present invention is not negated by the presence of natural insulin-producing cells (e.g., β cells) in the population. It is also expected that, for example, the insulin-producing cell population produced by the method disclosed herein can include mature pancreatic β cells, and can also include non-insulin-producing cells (i.e., cells with β-cell-like phenotypes but not producing or secreting insulin).
[0057] In the context of cellular ontogeny, the adjective "differentiated" or "differentiated" is a relative term, meaning that a "differentiated cell" is a cell that is further along in the developmental process than the cell to which it is being compared. Thus, a stem cell can differentiate into a lineage-restricted precursor cell (such as a mesodermal stem cell), which can further differentiate into other types of precursor cells (such as a cardiomyocyte precursor), and then differentiate into a terminally differentiated cell that will play a characteristic role in certain tissue types and may or may not retain the ability to expand further.
[0058] The term "cell culture medium" as referred to herein (also referred to herein as "culture matrix" or "culture medium") is a culture medium for culturing cells that contains nutrients to maintain cell viability and support proliferation. The cell culture medium may contain any of the following in appropriate combinations: salts, buffers, amino acids, glucose or other sugars, antibiotics, serum or serum substitutes, and other components, such as peptide growth factors, etc. Cell culture media commonly used for specific cell types are known to those skilled in the art. Exemplary basal culture media used herein include DMEM / F-12 (Dulbecco's Modified Eagle Medium / Nutrient Mixture F-12; available from Thermo Fisher Scientific). The basal medium may be supplemented with one or more of the following: a suitable buffer (e.g., HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid)), chemically defined supplements such as N2 (0.1-10%, e.g., 1%) and B27 (0.1-10%, e.g., 1%) serum-free supplements (available from Thermo Fisher Scientific), antibiotics such as penicillin / streptomycin (0.1-10%, e.g., 1%), MEM non-essential amino acids (Eagle's Minimal Essential Medium (MEM), which consists of a balanced salt solution, amino acids, and vitamins that are essential for the growth of cultured cells and, when supplemented with non-essential amino acids, yields a MEM non-essential amino acid solution), glucose (0.1-10%, e.g., 0.30%), L-glutamine (e.g., GlutaMAX TM ), ascorbic acid and / or DAPT (N-[N-(3,5-difluorophenylacetyl)-l-alanyl]-S-phenylglycine tert-butyl ester). Factors inducing differentiation as disclosed herein, such as Wnt agonists, such as CHIR99021, or Wnt substitutes, such as NGS, TGF-β pathway inhibitors, such as SB431542 or A83-01, Rho-ROCK pathway inhibitors, such as Y27632, Bmp inhibitors, such as Noggin, EGF (epidermal growth factor), insulin transferrin selenium mixture (ITS, available from Sigma), FGF2 (fibroblast growth factor 2), heparin, Y27632 and B27 can also be added to the culture medium.
[0059] The term "cell line" refers to a population of substantially or essentially identical cells, which are typically derived from a single ancestral cell or from a defined and / or substantially identical population of ancestral cells. A cell line may have been or may be able to be maintained in culture for a long time (e.g., months, years, indefinitely). It may have undergone a spontaneous or induced transformation process, thereby conferring an unlimited culture lifespan to the cells. Cell lines include all cell lines recognized in the art. It should be understood that cells acquire mutations and possible epigenetic changes over time, such that at least some properties of individual cells of a cell line may differ from one another. In some embodiments, a cell line comprises Procr + An endocrine progenitor cell, as described in any embodiment described herein.
[0060] "Organoid" refers to a three-dimensional multicellular in vitro construct that mimics an organ in vivo to some extent. For example, a pancreatic organoid contains cells that mimic the function of pancreatic islet cells. As used herein, "mature organoid" refers to an organoid cultured in a differentiation medium. In some embodiments, a mature organoid has a gene expression signature similar to or identical to the organ it mimics.
[0061] The terms "isolated," "purified," or "biologically pure" refer to material that is free to varying degrees from components that normally accompany it in its native state. "Isolate" means a degree of separation from the original source or surrounding environment. "Purify" means a degree of separation greater than isolation. A "purified" or "biologically purified" protein is completely free of other materials so that any impurities do not substantially affect the biological properties of the protein or cause other adverse consequences.
[0062] As used herein, the term "isolated cell" refers to a cell that has been removed from the organism in which it was originally found, or a descendant of such a cell. Optionally, the cell has been cultured in vitro, for example in the presence of other cells. Optionally, the cell is subsequently introduced into a second organism or reintroduced into the organism from which it was isolated (or the cell from which it was isolated).
[0063] As used herein, the term "isolated population" with respect to an isolated cell population refers to a cell population that has been removed and separated from a mixed or heterogeneous cell population. In some embodiments, an isolated population is a substantially pure cell population compared to a heterogeneous population from which cells are isolated or enriched.
[0064] With respect to a particular cell population, the term "substantially pure" refers to a cell population that is at least about 75%, preferably at least about 85%, more preferably at least about 90%, and most preferably at least about 95% pure relative to the cells that make up the total cell population. +For endocrine progenitor cells, the term "substantially pure" or "substantially pure" refers to a population of cells that contains less than about 20%, more preferably less than about 15%, 10%, 8%, 7%, and most preferably less than about 5%, 4%, 3%, 2%, 1%, or less than 1% of non-Procr + Endocrine progenitor cells. In some embodiments, the present disclosure includes amplifying Procr + Methods for endocrine progenitor cell populations, wherein Procr + The expanded population of endocrine progenitor cells is essentially pure Procr + Endocrine progenitor cell population.
[0065] The terms "enrich" or "enriched" are used interchangeably herein and mean that the yield (fraction) of one type of cells is increased by at least 10% over the fraction of that type of cells in the starting culture or preparation.
[0066] The terms "renewal" or "self-renewal" or "proliferation" are used interchangeably herein to refer to the ability of stem or progenitor cells to self-renew by dividing into the same non-specialized cell type over a long period of time and / or months to years. In some cases, proliferation refers to the expansion of cells by repeated division of a single cell into two identical daughter cells.
[0067] The terms "diabetes" and "diabetes mellitus (DM)" are used interchangeably in this article. The World Health Organization defines diabetes as a fasting blood glucose concentration of 7.0 mmol / l (126 mg / dl) and above (6.1 mmol / l or 110 mg / dl in whole blood) or a 2-hour blood glucose level of 11.1 mmol / L or higher (200 mg / dL or higher). Other values suggestive of or indicating a high risk of diabetes include elevated arterial pressure of 140 / 90 mm Hg or higher; elevated plasma triglycerides (1.7 mmol / L; 150 mg / dL) and / or low HDL-cholesterol (less than 0.9 mmol / L, 35 mg / dl in men; less than 1.0 mmol / L, 39 mg / dL in women); central obesity (men: waist-to-hip ratio greater than 0.90; women: waist-to-hip ratio greater than 0.85) and / or a body mass index greater than 30 kg / m 2 ; microalbuminuria with a urinary albumin excretion rate of 20 μg / min or greater, or an albumin:creatinine ratio of 30 mg / g or greater). The term diabetes mellitus includes all forms of diabetes mellitus, such as type I, type II, and type 1.5.
[0068] The terms "subject" and "individual" are used interchangeably herein and refer to an animal, such as a human, from which cells are obtained and / or treated with the cells described herein, including providing prophylactic treatment. For treatment of those infections, disorders, or disease states that are specific to a particular animal, such as a human subject, the term subject refers to that particular animal. "Non-human animals" and "non-human mammals" as used interchangeably herein include mammals, such as rats, mice, rabbits, sheep, cats, dogs, cattle, pigs, and non-human primates. The term "object" also encompasses any vertebrate, including but not limited to mammals, reptiles, amphibians, and fish. However, advantageously, the subject is a mammal, such as a human, or other mammals, such as domesticated mammals, such as dogs, cats, horses, etc., or production mammals, such as cattle, sheep, pigs, etc.
[0069] As used herein, the term "treatment" refers to administering an effective amount of a composition to a subject, so that the subject has a reduction in at least one symptom of the disease or an improvement in the disease, for example, a beneficial or desired clinical outcome. For the purposes of the present invention, beneficial or desired clinical outcomes include, but are not limited to, alleviating one or more symptoms, alleviating the extent of the disease, stabilizing (i.e., not worsening) the disease state, delaying or slowing the progression of the disease, improving or alleviating the disease state, and alleviating (whether partial or complete), whether detectable or undetectable. Treatment may refer to prolonged survival compared to the expected survival without treatment. Therefore, those skilled in the art recognize that treatment can improve the disease condition, but may not be a complete cure for the disease. As used herein, the term "treatment" includes prevention. Alternatively, if the progression of the disease is reduced or stopped, the treatment is "effective." "Treatment" may also refer to prolonged survival compared to the expected survival without treatment. People in need of treatment include those who have been diagnosed with heart disease, as well as those who may develop heart disease due to genetic susceptibility or other factors (such as weight, diet and health).
[0070] As used herein, the terms "administer," "introduce," and "transplant" are used interchangeably to describe placing cells (e.g., pancreatic organoids) of the present disclosure in a subject, by a method or approach of positioning the introduced cells at least in part at a desired location. Cells (e.g., pancreatic organoids, pancreatic β cells, or pancreatic β-like cells) can be implanted directly into the pancreas, or administered by any suitable route that delivers the cells to a desired location of the subject, wherein at least a portion of the implanted cells or cell components remain viable. The survival period of the cells after administration to the subject can be as short as a few hours, e.g., twenty-four hours, to a few days, to as long as several years. In some cases, the cells can also be administered, for example, in a capsule (e.g., a microcapsule) at a non-pancreatic location, such as in the liver or subcutaneously, to maintain the implanted cells at the implantation location and to avoid migration of the implanted cells.
[0071] An "effective amount" refers to the amount required to improve the symptoms of a disease relative to an untreated patient. The effective amount of an active compound used to practice the present invention to treat a disease depends on the mode of administration, the age, weight, and general health of the subject. Ultimately, the attending physician or veterinarian will determine the appropriate amount and dosage regimen. This amount is referred to as an "effective" amount.
[0072] The ranges provided herein are understood to be shorthand for all values within the range. For example, a range of 1 to 50 is understood to include any number, combination of numbers, or subrange selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50.
[0073] As used herein, the terms "comprising" or "including" are used with respect to the compositions, methods, and their respective components present in a given embodiment and are open ended and may include unspecified elements.
[0074] As used herein, the term "consisting essentially of" refers to those elements required for a given embodiment. The term permits the presence of additional elements that do not materially affect the basic and novel or functional characteristics of the embodiment of the disclosure.
[0075] The term "consisting of" refers to the compositions, methods, and respective components thereof described herein, to the exclusion of any elements not recited in the description of that embodiment.
[0076] In this specification and the appended claims, the singular forms "a", "an", and "the" include plural references unless expressly stated otherwise. Thus, for example, "the method" includes one or more methods, and / or steps of the type described herein that will become apparent to those skilled in the art upon reading this disclosure and the like.
[0077] Various aspects and embodiments are described in more detail in the following subsections.Any composition or method provided herein can be combined with one or more of any other compositions and methods provided herein.
[0078] Procr + Endocrine progenitor cells
[0079] Surprisingly, Procr +Endocrine progenitor cells are present in the adult pancreas as a small fraction of cells (about 1-3%) present in the islets. Procr is a Wnt target gene encoding a protein located on the surface of endocrine progenitor cells. Human PROCR is a highly glycosylated type I transmembrane protein with 238 amino acids (UniProtKB ID No.Q9UNN8). These amino acids include a signal peptide (amino acid 1017), an extracellular domain (amino acids 18-210), a 21-aa transmembrane domain (amino acids 211-231) and a 7-aa intracytoplasmic sequence (amino acids 232-238) that together encode a protein of approximately 46 kDa. Deglycosylation reduces the protein mass to 25 kDa.
[0080] PROCR is a receptor for protein C, which is a key protein in the anticoagulation pathway. The protein C anticoagulation pathway serves as a major system for controlling thrombosis, limiting inflammatory responses, and potentially reducing endothelial cell apoptosis caused by inflammatory cytokines and ischemia. The basic components of this pathway include thrombin, thrombomodulin, PROCR, protein C, and protein S. This pathway is initiated when thrombin binds to thrombomodulin on the endothelial surface. PROCR enhances the activation of protein C by binding to protein C and presenting it to the thrombin-thrombomodulin activation complex. Activated protein C (aPC) retains its ability to bind to PROCR, and this complex appears to be involved in some cell signaling mechanisms that downregulate the formation of inflammatory cytokines (TNF, IL-6). PROCR is shed from the vascular system by inflammatory mediators and thrombin. PROCR binds to activated neutrophils in a process involving proteinase 3 and Mac-1.
[0081] PROCR can be cleaved to release a soluble form (sPROCR) in the circulation. This sPROCR is detected as a single species of 43 kDa, which is due to the shedding of membrane PROCR by the action of metalloproteinases, which are stimulated by thrombin and some inflammatory mediators. Soluble PROCR binds PC and aPC with similar affinity, but its binding to aPC inhibits the anticoagulant activity of aPC by blocking its binding to phospholipids and by eliminating its ability to inactivate factor Va. sPROCR can be detected in plasma. In normal people, the level of sPROCR is 83.6+ / -17.2ng / ml. Elevated sPROCR levels are positively correlated with increased risk of thrombosis. In addition, a haplotype (A3 allele) is associated with increased sPROCR levels (264+ / -174ng / ml).
[0082] The full gene sequence of human Procr is 44819 bp (GenBank ID No. NC_000020.11). The sequence length of human CDNA is 717 bp (GenBank ID No. NM_006404.4). The full gene sequence of mouse Procr gene is 4354 bp (GenBank ID No. NC_000068.7).
[0083] In some embodiments, Procr isolated from mouse pancreas + Cells can express R-spondin1 (Rspo1), fibroblast growth factor 1 (Fgf1), Uroplakin 3B (Upk3b), Homeobox A5 (Hoxa5) and mesothelin (Msln) (as well as Figure 2F The expression of these genes constitutes a unique and previously unreported expression signature of these progenitor cells. + Progenitor cells can exhibit EMT characteristics. In some embodiments, EMT features include co-expression of epithelial markers EpCam, Krt8 and Cldn10 and mesenchymal markers Mmp2, Colla1 and Vim. EMT plays a key role in islet formation. Before endocrine islets are formed, committed endocrine precursor cells may detach from the trunk epithelium through EMT. It has also been suggested that, in the later stages, ductal cells can act as facultative endocrine progenitor cells, which are thought to occur by reawakening the embryonic EMT process. Under specific culture conditions, β cells can undergo EMT and dedifferentiate, thereby losing their mature characteristics. The resulting fibroblast-like cells can be extensively expanded and redifferentiated into endocrine cell types.
[0084] Procr + Cells derived from Ngn3 + Cells, Ngn3 + The cells appear to be in a partial EMT state, co-expressing epithelial and mesenchymal markers. + The cells are present in the embryonic endocrine progenitor cell population and have similar EMT features and shared signature genes such as Procr, Rspo1, Hoxa 5, and Decorin (Dcn). Ngn3 + Endocrine precursors represent a transient cell type in the embryonic pancreas. Although most Ngn3 + Endocrine precursors lose their precursor state upon maturation into endocrine cells, but a subpopulation appears to remain in the endocrine progenitor state after organogenesis. This reserve population does not express Ngn3, but it retains EMT features and gene expression signatures.
[0085] These Procr + Cells can be isolated from adult pancreas using the methods described herein. In various aspects of the present disclosure, Procr + Endocrine progenitor cells are isolated and then cultured under conditions suitable for generating pancreatic organoids. In some embodiments, mouse Procr + Endocrine progenitor cells also express one or more of Procr, Rspo1, Hoxa 5, and Dcn. In some embodiments, Procr can be isolated from pancreatic islets by contacting the cells with an antibody that specifically binds Procr. + In some embodiments, Procr + Progenitor cells were isolated by fluorescence activated cell sorting (FACS).Other methods known in the art for isolating cells based on marker expression are also encompassed herein.
[0086] MSLN + Endocrine progenitor cells
[0087] Another unexpected discovery was the MSLN + Endocrine progenitor cell populations exist in the adult pancreas as a small fraction of cells (about 3-5%) present in the islets. In some embodiments, the endocrine progenitor cells are Procr + and MSLN + .
[0088] The mesothelin (MSLN) gene encodes a 71-KD precursor (UniProtKB ID No. Q9UNN8), which is a glycosylphosphatidylinositol (GPI)-anchored membrane glycoprotein that is cleaved at arginine 295 (Arg 295) into two products: a soluble 31-KD N-terminal protein called megakaryocyte potentiating factor (MPF) and a 40-KD membrane-bound fragment called MSLN (mesothelin). Both MPF and MSLN have biological activities, but their exact functions remained unclear before this disclosure. MPF acts as a cytokine that can stimulate colony formation of bone marrow megakaryocytes, while its activity in humans is unknown. MSLN was originally described as a membrane protein expressed on mesothelioma and ovarian cancer cells, as well as normal mesothelial cells.
[0089] MSLN is expressed in trace amounts in normal mesothelial cells of the pleura, pericardium, and peritoneum, as well as in epithelial cells of the ovaries, vaginal membranes, rete testis, and surface of the fallopian tubes. In contrast, aberrant overexpression of MSLN has been observed in various cancer cells. In addition, MSLN is shed into the serum of patients with solid tumors, referred to as soluble MSLN-related protein (SMRP). The production of SMRP may be associated with abnormal splicing, which results in a secreted form or its cleavage from the membrane by the TNFα-converting enzyme ADAM17. SMRP has also been identified as a cancer biomarker in the serum of mesothelioma patients, where elevated levels of SMR in serum are associated with advanced stages and increased disease burden. However, the sensitivity and specificity of SMRP as a tumor marker for ovarian cancer are limited. The value of soluble MSLN in the diagnosis and prediction of cancer progression remains to be determined.
[0090] The full gene sequence of human MSLN is 8132 bp (GenBank ID No. NC_000016.10). The length of the human MSLN cDNA sequence of variant 1 is 1869 bp (GenBank ID No. NM_005823.6) or the length of variant 2 is 1893 bp (GenBank ID No. NM_013404.4).
[0091] The complete gene sequence of mouse Msln is 5766 bp (GenBank ID No. NC_000083.6). The length of mouse Msln cDNA sequence of variant 1 is 1878 bp (GenBank ID No. NM_001356286.1) or the length of variant 2 is 1890 bp (GenBank ID No. NM_001374653.1).
[0092] In some embodiments, MSLN isolated from human pancreas +The cells may express one or more of the following: UPK1B (uroplakin The expression of the genes S100A6 (S100 calcium-binding protein A6), LGALS4 (galectin 4), SDCBP2 (single-binding protein 2), SDC1 (syndecan 1), IGFBP3 (insulin-like growth factor binding protein 3), HMGA1 (high-mobility group A-hook 1), ITGB4 (integrin subunit 4), ITGB6 (integrin subunit 6), HN1 (hematologically and neurologically expressed 1), GPRC5A (G protein-coupled receptor class C group 5 member A), SLPI (secretory leukocyte peptidase inhibitor), LAMC2 (laminin subunit gamma-2), FERMT1 (ferritin family member), MGLL (monoglyceride lipase), MSLN (mesothelin), SEMA3B (semaphorin 3B), TST (thiosulfate sulfurtransferase), SFN (stratin), and CDH3 (cadherin 3) constitute a unique and previously unknown expression signature of these endocrine progenitor cells.
[0093] These MSLN + Cells can be isolated from adult pancreas using the methods described herein. In various aspects of the present disclosure, MSLN + Endocrine progenitor cells are isolated and then cultured under conditions suitable for generating pancreatic islet organoids. + Endocrine progenitor cells also express one or more of UPK1B, S100A6, LGALS4, SDCBP2, SDC1, IGFBP3, HMGA1, ITGB4, ITGB6, HN1, GPRC5A, SLPI, LAMC2, FERMT1, MGLL, MSLN, SEMA3B, TST, SFN, CDH3, and PROCR. In some embodiments, MSLN can be isolated from pancreatic islets by contacting the cells with an antibody (or an antigen-binding fragment thereof) that specifically binds to MSLN, such as an anti-human MSLN antibody (Biolegend, Cat#530203). + In some embodiments, MSLN + Progenitor cells can be isolated by fluorescence activated cell sorting (FACS).Other methods known in the art for isolating cells based on marker expression are contemplated herein.
[0094] Organoid production
[0095] Identification of endocrine progenitor cell pools in the pancreas (e.g., Procr + and / or MSLN +Endocrine cells) allow for in situ or ex vivo expansion methods to increase beta cell mass. The expansion and differentiation capacity of endocrine progenitor cells can be used to establish an expansion and induced culture system for islet-like organoids. The resulting organoids are primarily beta cells surrounded by alpha, delta, and PP cells, which is important for organoid function because proper glucose regulation requires coordination between the various islet cell types.
[0096] Separated Procr + And / or MSLB+ cells can be used to generate organoids that exhibit pancreatic function (e.g., glucose transport and insulin production and secretion). In some embodiments, Procr + And / or MSLN+ endocrine progenitor cells can be isolated and cultured from adult pancreatic islet cells to produce organoids of the present disclosure, which can be obtained from any pancreatic source. For example, pancreatic islet cells can be obtained from commercial sources or human sources. In some embodiments, the source of pancreatic islet cells is a human cadaver. In some embodiments, the source of pancreatic islet cells is a human patient with abnormal pancreatic function (e.g., a patient with type 1 or type 2 diabetes, or a patient with MODY (maturity-onset diabetes of the young)). Procr present in the islets obtained from human patients + and / or MSLN + Endocrine progenitor cells can be cultured to generate organoids that include glucose-sensitive pancreatic islet cells (ie, beta-like cells) that produce insulin.
[0097] Generally, in order to form an organoid, the separated cells are first expanded. In order to expand cells (i.e., to form colonies of separated cells), cells are cultured in organoid culture medium under conditions suitable for cell growth and reproduction. Organoid culture medium can be a serum-free culture medium supplemented with growth factors to promote cell growth and reproduction. In some embodiments, the organoid culture medium does not include differentiation factors sufficient to cause cell differentiation. In some embodiments, the organoid culture medium does not contain differentiation factors. Growth factors that can be used for organoid culture medium include but are not limited to Wnt agonist CHIR99021 or NGS, TGF-β pathway inhibitor SB431542 or A83-01, Rho-ROCK pathway inhibitor Y27632, Bmp inhibitor Noggin, EGF (epidermal growth factor), ITS, FGF2 (fibroblast growth factor 2), heparin, activation antibodies of integrin β1, and B27. In addition, growth-promoting conditions can include any conditions (e.g., culture medium, incubation time, culture medium replacement frequency, etc.) that activate Wnt, FGF, integrin and / or BMP signaling pathways. Growth-promoting conditions may need to suppress other cell signaling pathways. For example, in some embodiments, growth promoting conditions can include inhibition of the TGFβ and / or Rho-ROCK pathway.
[0098] An exemplary organoid medium for culturing mouse cells is DMEM / F12 (with penicillin-streptomycin) plus 1-5% (e.g., 2%) B27, 0.1-5% (e.g., 1%) ITS, 10-200 (e.g., 50) ng ml -1 EGF, 0.1-5 (e.g., 2) μg ml -1 Heparin, 1-50 (e.g., 10) ng ml -1 FGF2 and 1-20 (e.g., 5) ng ml -1 VEGFa. Another exemplary organoid medium for culturing human cells is DMEM / F12 (with penicillin-streptomycin) plus 1-5% (e.g., 2%) B27, 0.1-5% (e.g., 1%) ITS, 10-200 (e.g., 50) ng ml -1 EGF, 0.1-5 (e.g., 2) μg ml -1 Heparin, 1-50 (e.g., 10) ng ml -1 FGF2, 1-10 (e.g., 3) μM CHIR99021, 1-10 (e.g., 2) μM A83-01, 10-500 (e.g., 100) ng ml -1 Noggin, 1-50 (e.g., 10) μM Y27632.
[0099] The isolated progenitor cells can be cultured in a microenvironment that simulates at least a portion of the cellular niche in which the cells naturally exist. The cellular niche can be simulated by culturing stem cells in the presence of biomaterials, such as matrices, scaffolds, and culture substrates that represent key regulatory signals that control cell fate. The biomaterials can be natural, semisynthetic, and synthetic biomaterials, and / or mixtures thereof. The scaffolds provide two-dimensional or three-dimensional networks. Synthetic materials suitable for scaffolds include polymers selected from porous solids, nanofibers and hydrogels, such as peptides, including self-assembling peptides, hydrogel-polymers composed of polyethylene glycol phosphate, polyethylene glycol fumarate, polyacrylamide, polyhydroxyethyl methacrylate, polycellulose acetate and / or copolymers (see, for example, Saha et al., 2007, Curr. Opin. Chem. Biol. 11 (4): 381-387; Saha et al., 2008, Biophysical Journal 95: 4426-4438; Little et al., 2008, Chem. Rev. 108, 1787-1796). As known to those skilled in the art, the mechanical properties of the scaffold, such as elasticity, affect the proliferation, differentiation and migration of stem cells. Preferred scaffolds include biodegradable (co)polymers, which are replaced by naturally occurring components after being transplanted into a subject, for example to promote tissue regeneration and / or wound healing. Further preferably, the scaffold does not substantially induce an immunogenic response after being transplanted into a subject. The scaffold can be supplemented with natural, semisynthetic or synthetic ligands that provide the signals required for stem cell proliferation and / or differentiation and / or migration. In a preferred embodiment, the ligand comprises a defined amino acid fragment. Examples of synthetic polymers include F127 block copolymer surfactant (BASF) and (Johnson and Johnson).
[0100] The cell niche is determined in part by the extracellular matrix (ECM) produced by the progenitor cells and surrounding cells and by the cells in the niche. In some embodiments, the separated cells are attached to the ECM. The ECM is composed of a variety of polysaccharides, water, elastin and glycoproteins, wherein the glycoproteins include collagen, actin (nestin), fibronectin and laminin. The ECM is secreted by connective tissue cells. Different types of ECM are known, including different components, including different types of glycoproteins and / or different glycoprotein combinations. The ECM can be provided by culturing ECM-producing cells, such as fibroblasts, in a container, then removing these cells and adding separated progenitor cells. Examples of cells producing extracellular matrix are chondrocytes, which mainly produce collagen and proteoglycans, fibroblasts, which mainly produce type IV collagen, laminin, interstitial procollagen and fibronectin, and colonic myofibroblasts, which mainly produce collagen (I, III and V types), chondroitin sulfate proteoglycans, hyaluronic acid, fibronectin and tenascin-C. Alternatively, ECM can be commercially available. Examples of commercially available extracellular matrices are extracellular matrix protein (Invitrogen) and Matrigel TM (BD Biosciences). Using ECM to culture progenitor cells enhances long-term survival of cells and the persistence of undifferentiated cells. In addition, the presence of ECM allows the culture of three-dimensional tissue organoids.
[0101] In some embodiments, an ECM suitable for use may include at least two different glycoproteins, such as two different types of collagen or collagen and laminin. The ECM may be a synthetic hydrogel extracellular matrix or a naturally occurring ECM. Matrigel TM (BD Biosciences) provides an exemplary ECM comprising laminin, entactin, and collagen IV.
[0102] In some embodiments, the isolated Procr + and / or MSLN + The cells can be co-cultured with endothelial cells at a ratio of about 1: 10 to about 10: 1, such as about 1:5, about 1:3, or about 1: 1. Endothelial cells provide key niche components, and in some embodiments, the co-culture medium is supplemented with VEGFa.
[0103] Organoids can be passaged every 5-30 days to expand. For passage, organoids can be released from the matrigel using dispase and dissociated into single cells (e.g., using trypsin-EDTA). The single cell suspension can then be mixed with freshly isolated CD31+ECs in a 1:1 ratio and then re-coated at a split ratio of about 1:2-1:10, or about 1:3-1:8, or about 1:4-1:6. Organoids can be passaged at least 20 times (about 6 months), at least 30 times, or indefinitely without slowing down the expansion rate.
[0104] This expansion duration provides organoids with time to mature, allowing β-like cells to produce and secrete insulin in response to glucose stimulation. These passaged organoids can then be taken out of the amplification cycle and matured for an additional period of time (e.g., about 1-4 weeks or about 2-3 weeks or about 3 weeks (28-30 days after reseeding as a single cell)), and mature organoids may look similar to primary organoids. In some embodiments, organoids are tested to determine their ability to produce and secrete insulin. In some embodiments, the test is performed in vitro. In some embodiments, the test is performed in vivo, for example, after the organoid is transplanted into a recipient (e.g., mouse or human). Insulin and / or secretion produced in or by organoids can be assessed by any technique known in the art. For example, the expression of insulin can be assessed by enzyme-linked immunosorbent assay (ELISA) or other immunoassays, which utilize antibodies that specifically bind insulin (or another molecule of interest expressed in organoids, including but not limited to glucagon, somatostatin, and pancreatic polypeptide). In some embodiments, the detection of insulin production in organoids can be assessed in vitro by obtaining at least one organoid in culture and directly testing it. Insulin secretion of organoids can be detected in vitro in culture medium by any means known in the art. For example, the culture can be centrifuged and tested for insulin in the supernatant that does not contain (or is substantially free of) organoids. In some embodiments, the in vivo insulin production of transplanted organoids can be assessed by analyzing blood sampling from subjects who have received organoid treatment of the present disclosure and comparing with insulin levels in subjects before treatment. The measurements are routine in the art.
[0105] Using insulin-producing organoids
[0106] From Procr + and / or MSLN + Endocrine progenitor cells, such as the organoids described herein or produced using the methods described herein, can be used as therapeutic and preventive organoids for the treatment and prevention of diabetes mellitus (DM) or any disease or condition responsive to insulin production as described herein.
[0107] The number of organoids described herein in the pharmaceutical composition necessary to achieve the best or satisfactory results may vary depending on the subject being treated. For example, the number of organoids required for a person who completely loses endogenous insulin production may be less than the number of organoids required for a patient who retains at least some endogenous insulin production. In some embodiments, the number of organoids present in the pharmaceutical composition may be between about 100 and about 10,000,000 organoids, about 1,000-1,000,000 organoids, or about 10,000-100,000 organoids, or any smaller, larger or between the two. Determining the exact effective dose can be based on factors for each individual subject, including their size, age, sex, weight and condition. Those skilled in the art can easily determine the dosage from the present disclosure and knowledge in the art. Those skilled in the art can also easily determine the number of organoids in the composition and in the method of the present invention and the amount of optional additives, vehicles and / or carriers.
[0108] The present disclosure is characterized by compositions and methods for the treatment of diabetes. More specifically, the above-mentioned organoids are administered to people in need (e.g., human diabetics), which can improve, reduce or otherwise treat or prevent abnormal pancreatic function in patients. In some embodiments, organoids are derived from endocrine progenitor cells obtained from patients, optionally followed by gene editing such as CRISPR to correct mutations (if any). Obtaining autologous islet cells from patients can reduce the risk of organoid rejection in patients. In some embodiments, organoids are derived from endocrine progenitor cells obtained from heterologous human subjects (e.g., organoid banks or libraries).
[0109] Administration of the organoids of the present disclosure for the treatment of diabetes (or any other disease or condition that may be responsive to organoids) can be by any suitable means that results in a concentration of the therapeutic organoid effective to improve, treat, or prevent diabetes.
[0110] In some embodiments, the organoids are transplanted directly into the patient's pancreas or other parts of the body, such as the liver, spleen, renal capsule, omental bag, skin, muscle, bone marrow (see, e.g., doi: 10.3389 / fmed.2018.00202, which is incorporated by reference and as herein). Anti-rejection drugs can also be administered to the subject to reduce the likelihood that the transplanted organoids will be rejected by the patient's immune system.
[0111] In one aspect, the invention provides a method for monitoring the progress of treatment. The method includes the step of determining insulin (or other markers (e.g., glucagon, somatostatin or pancreatic polypeptide) or diagnostic measurements (e.g., screening, assaying) levels) in a subject suffering from or susceptible to diabetes, or other diseases or symptoms associated with impaired pancreatic islet function, wherein the subject has been administered a ProcRx disclosed herein sufficient to treat the disease or its symptoms. + and / or MSLN + The effective amount of organoid. The insulin (or other marker) level determined in the method can be compared with the known insulin level in a healthy normal control or other sick patients to determine the disease state of the subject. In another embodiment, the second level of insulin in the subject is determined at the time point after determining the first level, and the two levels are compared to monitor the effect of disease progression or treatment. In some preferred embodiments, the pre-treatment level of insulin (or other marker) in the subject is determined before starting treatment according to the present invention; Then the insulin (or other marker) level before the treatment can be compared with the insulin (or other marker) level in the subject after the treatment starts, to determine the effect of treatment.
[0112] Screening test
[0113] Some aspects of the present disclosure provide screening assays wherein Procr + and / or MSLN + The endocrine progenitor cells or organoids disclosed herein are used in an in vitro environment to test the efficacy of insulin production agonists or antagonists or other compounds, compositions or agents for inducing or otherwise affecting the differentiation of pancreatic endocrine progenitor cells. In some embodiments, the organoids are derived from ProcRx obtained from healthy subjects. + and / or MSLN + Endocrine progenitor cells. In other embodiments, the organoid is derived from a subject suffering from diabetes or another disease or condition characterized by impaired islet function. If an insulin-producing agonist or other compound or composition is effective in promoting an increase in insulin, then insulin will accumulate in the culture medium and can be quantified. In some cases, the compound or composition administered to the organoid may be harmful to the health of the organoid. For example, the organoid may stop growing and / or reproducing, may exhibit an altered morphology, or may die. Such results indicate that the compound or composition has toxic characteristics.
[0114] In some embodiments, in vitro screening of organoids comprising the present disclosure can be used to better understand β cell or pancreatic islet function or other endocrine cell function. + and / or MSLN +Endocrine progenitor cells derived from a subject having a disease or condition (eg, diabetes) can be studied to better understand the molecular and cellular factors, including genetic mutations and microenvironmental factors, that contribute to the subject's disease or condition.
[0115] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the assays, screens and treatment methods of the invention, and are not intended to limit the scope of the invention. The inventors believe that their invention
[0116] Example
[0117] Example 1: From resident Procr + Long-term Expansion of Progenitor Cells in Pancreatic Islet Organoids
[0118] Procr in adult pancreatic islets + Progenitor cell population
[0119] Since Procr is a surface protein that has been reported to mark stem cells in several adult tissues, including the mammary gland (Wang et al., 2015), endothelial cells (Yu et al., 2016), and the hematopoietic system (Balazs et al., 2006; Fares et al., 2017; Iwasaki et al., 2010; Zhou et al., 2016), we searched for Procr-positive cells in mouse islets using single-cell (sc) RNA sequencing. Pancreata from 8-week-old adult mice were isolated and enriched for endocrine cells (see Methods section below). 7,160 cells were analyzed using a single-cell RNA sequencing approach ( Figures 1A-1D Each cluster was mapped to a known abundant endocrine (α-, β-, δ-, and PP cells), abundant exocrine (acinar and ductal cells), or rare (mesenchymal, endothelial, immune, and stellate) cell type ( Figure 1D-1G ). Individual clusters contain cells that are distinct from any known cell population ( Figures 1F-1H ). This new cell population showed unique signature genes, including Rspo1, Fgf1, Upk3b, Hoxa5, and Procr( Figures 1H-1K ), but do not express known markers of endocrine or exocrine differentiation, as shown by t-distributed random neighbor embedding ( Figure 1D , 1E , 1G, 1K). Gene ontology (GO) analysis identified enrichment of cell migration, epithelial-mesenchymal transition (EMT), and Wnt signaling pathway-GO terms ( Figure 1L). The characteristic expression of Wnt agonist gene Rspo1 and Wnt target gene Procr indicated the enhanced activity of Wnt signaling pathway. t-SNE analysis showed that epithelial markers (EpCAM, Krt8 and Cldn10) and mesenchymal markers (Mmp2, Col1a1 and Vim) were co-expressed in the new cell population, which supported its EMT characteristics ( Figure 1M ).
[0120] EMT is associated with the formation of endocrine islets from committed endocrine precursor cells (Rukstalis and Habener, 2007). The lack of differentiation marker expression in the new population also suggests a potential precursor state. To gain insight into the nature of the new population, expression data were merged with previously reported embryonic endocrine progenitor cell datasets (Byrnes et al., 2018; Scavuzzo et al., 2018). The new population observed in the adult pancreas is similar to the Neurog3 (Ngn3) at day 14.5. + Cell clusters are consistent ( Figure 2A-2B Interestingly, this population at E14.5 also exhibited EMT characteristics, namely the combined expression of epithelial and mesenchymal markers ( Figure 2C ). The E14.5 colony is Ngn3 + , while the adult counterpart is Ngn3 - ( Figure 2D Importantly, the E14.5 populations shared a gene signature that included Rspo1, Fgf1, Dcn, Upk3b, Hoxa5, and Procr ( Figure 2E-2G ). The similarity of the E14.5 population to embryonic endocrine precursors suggests that Procr + The population represents a progenitor cell state. Therefore, the precursor-progenitor relationships between the identified endocrine populations were examined by pseudo-temporal analysis using Monocle 2 (Qiu et al., 2017). Two developmental trajectories were predicted: one towards β cells and one towards α cells ( Figure 2H-2I ).
[0121] Procr + Cell sorting
[0122] Islet and non-islet tissues were isolated by hand selection. Islet cell preparations underwent negative selection for lineage, positive selection for epithelial cells, and were further separated into ProcR + (Lin - EpCAM + ,Procr + ) and Procr - (Lin-,EpCAM + ,Procr - )group( Figure 3A-3B The anti-Procr antibodies used were PE or APC anti-mouse Procr (clone 1560) from eBioscience. A small population (1.0 ± 0.14%) of islet cells were Procr + ( Figure 3B-3C ). Considering that rare mesenchymal cells, stellate cells, and endothelial cells can express Procr, as shown by single-cell RNA sequencing ( Figure 1H ), Procr + and Procr - Cells were also isolated from non-islet cells. qPCR analysis showed that the signature genes of the new population, such as Rspo1, Fgf1, Upk3b, and Hoxa5, were expressed only in Procr + Expression in pancreatic islet cells ( Figure 3D ).
[0123] Next, we analyze Ngn3 - Cre;R26-tdTomato mice, in which all endocrine lineages are marked in tdTomato and thus are derived from embryonic Ngn3 + Endocrine progenitor cells (Gu et al., 2002). FACS analysis confirmed that Procr + Islet cells are all tdTomato + ( Figure 3E ), and the cells were identified as Ngn3 + Remarkably, they appear to represent a novel progeny that lacks expression of α, β, δ, and PP cell differentiation markers.
[0124] To visualize this population, a dual reporter allele was generated with a membrane GFP (mGFP)-2A-LacZ cassette inserted at the ATG of Procr ( Figure 3F-3I As shown by whole mount X-gal staining, Procr expression occurs in a few cells in a dispersed pattern in the islets ( Figure 3J ) Further verification of mGFP using FACS with Procr antibody + cell( Figure 3K ). Staining of whole encapsulated islets confirmed mGFP + (Procr + ) cells do not express endocrine differentiation markers ( Figure 3L ), but co-expressed the epithelial marker EpCAM and the mesenchymal marker Col1a1 ( Figure 3M ), which is consistent with single-cell RNA sequencing analysis.
[0125] Single Procr+ islet cells form islet-like organoids in culture
[0126] Assume that Procr + Islet cells can be used as a source of new β cells in vitro. + Islet cells were isolated by FACS and plated at clonal density in 3D culture in serum-free medium supplemented with growth factors including B27, ITS, EGF, heparin, and FGF2. Although the colony formation efficiency of unsorted islet cells is very low (i.e., 1 colony formed from 2,000 total cells plated), Procr + The clonogenicity of pancreatic islet cells increased 130-fold (i.e., 1 in 15 plated cells formed a colony) ( Figure 4A ). In contrast, Procr - Islet cells cannot form colonies ( Figure 4B ). However, from unsorted islet cells or Procr + Islet cell colonies could not be maintained for more than 7 days.
[0127] Endothelial cells (ECs), proposed as key niche components, were then added to the co-culture (supplemented with VEGFa, see Methods section below). When co-cultured with ECs, Procr + Islet cells showed strong colony-forming ability (i.e., colony formation was achieved by 4 plated Procr + The cells formed 1 colony. Colonies were easily observed from the 5th day. By the 8th day, colonies with an average diameter of 145 μm were observed ( Figure 5A In contrast, Procr- islet cells remained as single cells ( Figure 5A ). + The cell-derived colonies were cultured for a total of 28 days under the same conditions. The formation of a more elaborate structure was observed: a large epithelial organoid in the center, surrounded and infiltrated by an endothelial network ( Figure 5B The average organoid diameter reached 210 μm ( Figure 5B-5C ), which is similar to the size of mouse islets in vivo.
[0128] Insulin (Ins) expression was examined as an indicator of functional β-cell formation. Ins staining was absent on day 7 and appeared at low levels on day 28 ( Figure 5D After glucose stimulation (incubation with low-concentration glucose for 12 h, followed by high-concentration glucose for 12 h, for a total of 3 rounds, see the Methods section below), Ins expression in organoids on day 28 reached levels comparable to those of freshly isolated islets ( Figure 5D-5EHowever, the same glucose stimulation treatment had only a modest effect on Ins expression in day 7 organoids, suggesting that prolonged culture is critical for β-cell formation. As measured by qPCR analysis, the key β-cell regulators MafA, Ucn3, and Pdx1 increased to similar levels in high-glucose-treated organoids at day 28 compared to freshly isolated islets ( Fig. 5F ). On day 28, organoids rapidly increased cytosolic Ca in response to glucose. 2+ concentration and then returned to baseline ( Figure 5G ), indicating that they are able to respond acutely to glucose (Mohammed et al., 2009). Ultrastructural analysis by transmission electron microscopy (TEM) revealed that day 28 organoids contained abundant endocrine granules ( Figures 5H-5I ). ELISA confirmed insulin secretion in the culture medium of organoids stimulated with glucose at day 28 ( Figure 5J ). In addition to the rich Instagram + In addition to β-like cells, organoids also contain lower amounts of glucagon (Gcg) + α-like cells, somatostatin (Sst) + Delta-like cells and pancreatic polypeptide (Ppy) + PP-like cells, reminiscent of the composition of fresh pancreatic islets ( Figure 5K-5N ). Therefore, the use of Procr + The cells were cultured in a system that demonstrated endocrine progenitor-like capabilities, which allowed the generation of pancreatic islet-like organoids in vitro. The cells within these organoids were able to produce packaged insulin granules, perform glucose sensing, and secrete insulin.
[0129] Pancreatic islet-like organoids can be expanded long-term in vitro
[0130] Organoids were expanded by passaging as described above. Isolated single cells were reseeded at a ratio of 1:4-6 (i.e., cells from 1 well were reseeded into 4-6 wells) every 7-8 days under the same culture conditions supplemented with fresh EC (see Methods section below). In this culture system, the average organoid size remained stable during passaging ( Fig. 6A , 6B However, the number of organoids increased 3- to 7-fold with each passage ( Figure 6C ). Organoids can be passaged for at least 20 times or for 6 months without a reduction in expansion rate ( Figure 6C ).
[0131] When passaged organoids were removed from the expansion cycle and allowed to mature for an additional 3 weeks (i.e., 28–30 days after being replated as single cells; see Fig.6D), mature organoids similar to the primary organoids described above appeared. Taking passage 7 and 15 organoids as an example, they showed similar percentages of α, β, δ, and PP cells compared to primary channel organoids ( Figure 6E-6H ), glucose detection and insulin secretion capacity, insulin granule number and Ca 2+ response( Figure 5G-5H , Figures 6I-6N ). These results indicate that the proliferation and differentiation capabilities of cells are maintained for a long time.
[0132] Long-term cultured organoids reverse diabetes in vivo
[0133] Long-term cultured organoids were transplanted into the kidney capsule of streptozotocin (STZ)-induced diabetic mice to test the full potential of the organoids. The mice were monitored for improvements in blood glucose. Each recipient mouse was transplanted with 1,000 organoids (from passage 7 or 15, harvested on day 7 of culture) or 300 freshly isolated islets, which contained similar cell numbers (approximately 300,000 cells). One week after transplantation, blood glucose levels were significantly reduced ( Fig. 7A ), weight loss stopped ( Figure 7B Glycemic improvements were maintained throughout the analysis period ( Fig. 7A ). Notably, the organoid transplantation group showed a similar rescue effect as the fresh islet transplantation group ( Fig. 7A and 7C At one month after transplantation, mice transplanted with organoids showed glucose clearance and serum insulin levels nearly identical to those of mice that received fresh islets ( Figure 7C-7D ). As a result, the transplanted organoids were able to secrete insulin and improve progressive hyperglycemia in a diabetic mouse model.
[0134] Transplanted organoids were removed and analyzed 1 month after transplantation. All four endocrine cell types were detected, with the vast majority being Ins + β cells ( Figure 7E-7F )As shown in TEM ( Figure 7G ), the transplanted cells also contained a high density of endocrine granules. The cells were further analyzed and identified by single-cell RNA sequencing. The transplanted cells aggregated with the primary endocrine cells after maturation in vivo ( Figures 7H-7K In particular, genes encoding islet cell markers, hormones, and transcriptional regulators were expressed at comparable levels between primary mouse endocrine cells and transplanted organoids ( Figure 7L-7N ).
[0135] discuss
[0136] In the current study, we identified a population of endocrine progenitor cells in the adult mouse pancreas. These cells do not express known mature endocrine cell markers, have EMT features, and express Procr on their surface. + Islet cells can be grown at clonal density into islet-like organoids that include all endocrine cell types and are able to detect glucose and secrete insulin. These organoids can be expanded exponentially in vitro through long-term serial passaging. Long-term cultured islet-like organoids can reverse diabetes in vivo.
[0137] EMT plays a key role in islet formation. Prior to endocrine islet formation, committed endocrine precursor cells may detach from the trunk epithelium via EMT (Rukstalis and Habener, 2007). It has also been proposed that at later stages, ductal cells can serve as facultative endocrine progenitors, which is thought to occur by reawakening the embryonic EMT process (Al-Hasani et al., 2013). Under specific culture conditions, β cells can undergo EMT, dedifferentiating and thereby losing their mature characteristics. The resulting fibroblast-like cells can be extensively expanded and redifferentiated into endocrine cell types (Gershengorn et al., 2004; Ouziel-Yahalom et al., 2006; Russ et al., 2008). In the present study, we identified a population of cells in healthy adult islets that appear to be in a partial EMT state, co-expressing epithelial and mesenchymal markers. Interestingly, there seems to be a corresponding cell population in the embryonic endocrine progenitor cell population, with similar EMT characteristics and shared signature genes, such as Procr, Rspo1, Hoxa 5, and Dcn. + Endocrine precursors represent a transient cell type in the embryonic pancreas. Although most Ngn3 + Endocrine precursors lose their precursor state after maturation into endocrine cells, but a subpopulation appears to remain in the endocrine progenitor state after organogenesis. This reserve population no longer expresses Ngn3, but it retains EMT features and signature genes that indicate EMT. - Cre-mediated lineage tracing confirmed that Procr + Cells (endocrine progenitor cells) from Ngn3 + Endocrine precursors.
[0138] We cannot formally exclude the ductal tree as an alternative source of these cells. Accumulating evidence suggests the presence of a pool of pancreatic progenitor cells within the ductal tree of the adult pancreas. Severe injury to the pancreas stimulates non-endocrine precursor cells, such as ductal cells, to proliferate and differentiate into acinar (Criscimanna et al., 2011; Furuyama et al., 2011), ductal (Criscimanna et al., 2011; Furuyama et al., 2011; Kopp et al., 2011), and endocrine lineages including beta cells (Criscimanna et al., 2011; Inada et al., 2008; Pan et al., 2013; Van de Casteele et al., 2013; Xu et al., 2008). In the present study, we used Procr + We analyzed endocrine progenitor cells after they were physically localized in islets. We visualized these cells using knock-in reporters of LacZ and mGFP, and we visualized EpCAM+ and Procr + These cells were isolated by FACS using surface markers and further investigated for their clonogenicity, expansion and multipotent endocrine lineage differentiation abilities in culture.
[0139] Identification of an endocrine progenitor cell pool within the pancreas itself would allow for in situ or ex vivo expansion approaches to increase β-cell mass. This study explored the latter possibility. We exploited the expansion and differentiation capacity of endocrine progenitor cells by establishing a culture system for the expansion and induction of islet-like organoids. The resulting organoids were primarily β-cells surrounded by an overlay of α, δ, and PP cells. We demonstrated that these organoids are a useful cell source for ameliorating diabetes in mouse models. Accumulating evidence suggests that proper glucose regulation requires coordination between the various islet cell types (Johnston et al., 2016; van der Meulen et al., 2015). Therefore, it may be advantageous to generate entire islets in vitro rather than differentiate cells into specific cell types.
[0140] In conclusion, this study identified a novel endocrine progenitor cell in the adult mouse pancreas and established an in vitro method for long-term expansion and induction of islet-like organoids. Ultimately, this progenitor cell population may be exploited for its presence in humans and for the treatment of diabetes.
[0141] method
[0142] Key Resources Table
[0143]
[0144]
[0145]
[0146]
[0147] Experimental Animals:
[0148] In this study, Rosa26-tdTomat, Ngn3 - Cre, Actin-DsRed, Procr mGFP-2A-LacZ , wild-type CD1, C57BL / 6, FVB / NJ and nude mice. mGFP-2A-Lacz The mouse strain was generated by knocking in the mGFP-2A-LacZ cassette after the start codon of the Procr gene. The targeting construct, Southern blot validation, and genotyping methods are shown in Figure 3G-3I All animal experimental procedures were approved by the Animal Care and Use Committee of the Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, with project license number IBCB0065.
[0149] Islet enrichment and purification
[0150] Mouse pancreas was perfused by injecting 2-4 ml of digestion buffer (DMEM 1640 medium containing type IV collagenase (1000-1500U / ml), 10% FBS (fetal bovine serum) and 25mM HEPES) through the common duct. The pancreas was then carefully dissected to maintain the integrity of the perfused tissue and then incubated at 37°C for 5-6 minutes, followed by gentle shaking for 3-6 minutes. Proper perfusion and digestion time is critical for islet yield and structural integrity. After digestion, the tissue was suspended in 20 ml HBSS containing 10% FBS and vigorously shaken up and down 40 times in 20 seconds, followed by two HBSS washes. The digested tissue was then filtered with a 500 μm cell strainer. To enrich for islets, the filtered sample was subjected to density gradient centrifugation or transferred to a microscope to manually pick islets. To prepare for density gradient centrifugation, the tissue was first resuspended in 10 ml histopaque-1077 and then slowly covered with 10 ml HBSS without disrupting the interface. The resuspended tissue was centrifuged at 2,400 rpm for 22 minutes with minimal acceleration and braking to obtain the enriched islet compartment at the HBSS / histopaque-1077 interface. After the density gradient centrifugation step, the purity of the islets was approximately 20% to 70%, depending on the quality of the early perfusion and digestion processes. To ensure high purity of the islets, the samples were resuspended in HBSS containing 10% FBS for hand picking. High purity islets were hand picked under a dissecting microscope for at least 3 rounds.
[0151] Islet X-gal staining
[0152] X-gal staining of purified islets was performed according to standard protocols with minor changes. Briefly, islets were fixed in Fix A solution (1% formaldehyde, 0.2% glutaraldehyde, 0.02% NP-40 in PBS) at 4°C for 30 min, washed three times with PBS, and then stained in X-gal staining solution (1 mg / ml X-gal, 5 mM K3[Fe(CN)6], 5 mM K4[Fe(CN)6], 2 mM MgCl2 in PBS) at room temperature for 5 h. After staining, islets were washed with PBS and whole mount images were taken using a Zeiss inverted microscope.
[0153] Immunofluorescence, whole mount staining, and microscopy
[0154] To prepare samples for cryosectioning, dissected pancreas were fixed in 4% PFA for 4 hours at 4°C, washed 3 times with PBS, and then embedded in optimal cutting temperature (OCT). Tissue sections were incubated with primary antibodies overnight at 4°C, then washed in PBST (PBS + 0.1% Triton-X 100), and incubated with secondary antibodies and DAPI for 2 hours at room temperature. The sections were then washed and mounted for confocal imaging.
[0155] For whole mount staining, islets or cultured organoids were fixed in 4% PFA for 1 hour at 4°C followed by 3 PBS washes. Islets or cultured organoids were then blocked with whole mount blocking buffer for 1 hour at room temperature. Blocking buffer contained 10% FBS in PBST. Primary antibodies were diluted in blocking buffer and incubated overnight at 4°C after 3 washes with PBST. Secondary antibodies and DAPI were incubated overnight at 4°C. Islets or organoids were then washed and mounted with mounting medium for confocal imaging.
[0156] All confocal images were captured by a Leica SP8 confocal detection system mounted on a Leica DMI6000 microscope.
[0157] Preparation of pancreatic islet single cell suspension and FACS analysis
[0158] The purified islet samples were treated with 2 ml of 0.05% trypsin-EDTA at 37°C for 4 minutes, and then digested with 0.1 mg / ml DNase I for 4 minutes and the samples were gently pipetted about 20 times. The digested cells were filtered through a 70 μm cell strainer.
[0159] For FACS analysis and cell sorting, antibodies were incubated on ice for 25 min in HBSS containing 5% FBS at a dilution of 1:200. All analysis and sorting experiments were performed using FACS Jazz (Becton Dickinson). The purity of the sorted population was routinely checked to ensure above 95%.
[0160] Co-culture and passaging of mouse pancreatic islet organoids
[0161] 200 μl of Matrigel was coated in one well of a 48-well plate and then transferred to a 37°C ESCO incubator for gelation. Mouse pancreatic islet EpCAM + 、Procr + / - Cells were FACS sorted from pancreatic islets of hand-picked wild-type CD1, C57BL / 6, or FVB mice. + Endothelial cells (ECs) were isolated from inguinal fat pads or the skin of Actin-DsRed mice. Islet cells and ECs were mixed in a 1:3 ratio and inoculated in 500 μl of mouse organoid culture medium containing DMEM / F12 (with penicillin-streptomycin) plus 2% B27, 1% ITS, 50 ng / ml EGF, 2 μg / ml heparin, 10 ng / ml FGF2 and 5 ng / ml VEGFa. The culture medium was renewed every 2-3 days. In order to induce β-cell maturation, glucose stimulation was performed. 20 mM glucose in HBSS was mixed with organoid culture medium in a 1:1 ratio to prepare a high-concentration glucose medium with a final concentration of 11 mM glucose. The organoids were first cultured in low-concentration glucose (2 mM) for 12 hours and then cultured in high-concentration glucose (11 mM) for 12 hours for 3 rounds.
[0162] Organoids were passaged every 6-14 days. For passaging, organoids were released from Matrigel using dispase (37°C for 40 minutes) and dissociated into single cells using 1 ml of 0.05% trypsin-EDTA (37°C for 6-9 minutes). Single cell suspensions were mixed with freshly isolated CD31+ECs at a 1:1 ratio and then re-seeded at a split ratio of 1:4-6.
[0163] Glucose-stimulated insulin secretion
[0164] Approximately 100 mouse organoids were used at day 28 of culture. The organoids were first washed 3 times with Krebs buffer and then pre-incubated in low glucose (2mM) for 2 hours to remove residual insulin. The organoids were then washed 2 times in Krebs buffer and then incubated in low glucose for 30 minutes. Supernatant samples were collected, the organoids were washed 2 times in Krebs buffer, then incubated in high glucose (20mM) for 30 minutes, and then the supernatant samples were collected. This process was repeated twice. Insulin levels in supernatant samples were analyzed using a mouse ultrasensitive insulin ELISA kit according to standard protocols.
[0165] Transmission electron microscopy (TEM).
[0166] To prepare TEM samples, organoids or islets were fixed in 1% glutaraldehyde in 0.1M sodium cacodylate buffer (pH 7.4) at 4°C overnight, and then fixed in 2% aqueous osmium tetroxide at 4°C for 1.5 hours. The samples were then dehydrated in gradual ethanol (30% to 100%) and propylene oxide, embedded in Epon812, and cured at 60°C for 48 hours. 50nm ultrathin sections were collected on 200 mesh copper grids and stained with uranyl acetate (10 minutes) and lead citrate (5 minutes), and then examined by transmission electron microscopy. Images were taken using a FEI Tecnai G2 Spirit transmission electron microscope.
[0167] Ca 2+ Imaging
[0168] Organoids were harvested after dispase dissociation and plated on 35 mm glass-bottom dishes without Matrigel for 24 h. The cell clusters were washed twice with Krebs buffer and incubated with Fluo4-AM for 30 min. Fluo4-AM was washed off with Krebs buffer and the cell clusters were incubated for another 15 min at 37 °C without dye. The cell clusters were then placed on a Nikon AI inverted confocal microscope to acquire high-resolution time-series images. Time-series images were acquired every 10 s. The conditions for the progression of glucose challenge and stimulation time during imaging were as follows: 5 min in low concentration glucose (2 mM), washed with Krebs, 5 min in high concentration glucose (20 mM), washed with Krebs. This sequential treatment was performed 3 times, followed by a final incubation of 5 min with 2 mM glucose containing 30 mM KCl. For the measurement of mean fluorescence intensity, images were quantified by Imaris software (v8.2.0).
[0169] Transplantation in diabetic mice
[0170] Diabetes was induced in nude recipients by a single intraperitoneal injection of streptozotocin (STZ, 160 mg / kg in pH 4.5 citrate buffer) 7 days before transplantation. Non-fasting blood glucose was measured from tail vein samples using a OneTouch blood glucose meter to select diabetic recipients whose blood glucose levels increased to approximately 20 mM. 300 mouse islets or 1,000 organoids (generation 7 or 15, cultured on day 7) were transplanted under the renal capsule of recipient mice. Non-fasting blood glucose and body weight were routinely measured 1 month after transplantation. Glucose tolerance test (GTT) was performed according to standard protocols 1 month after transplantation.
[0171] Briefly, mice were fasted overnight and received an intraperitoneal injection of 2 g glucose per kg body weight.
[0172] Blood glucose levels were measured at 0, 15, 30, 60, 90 and 120 minutes after glucose challenge. Serum samples were also collected before and after glucose injection and measured by ELISA. Recipients were sacrificed 1 month after transplantation and regenerated tissues were harvested for sectioning and endocrine marker staining or digested into single cells for transmission electron microscopy analysis and 10X sc RNA sequencing.
[0173] RNA isolation and PCR
[0174] RNA isolation from primary cells or organoids was performed following the manufacturer's instructions. Samples were lysed in RNAiso plus. Extracted RNA was reverse transcribed into cDNA using the Primerscript RT Master Kit. qPCR samples were prepared using SYBR GreenMixture and detected using an Applied Biosystems Stepone Plus machine. All qPCR primers are listed in the Key Resources table above.
[0175] Single-cell RNA sequencing using the 10X Genomics Chromium platform
[0176] For primary pancreatic single-cell RNAseq, 3 biological replicates were performed using ICR mice for replicates 1 and 2 and C57BL / 6 mice for replicate 3. Islets were enriched by density gradient centrifugation as described above. To minimize damage from exocrine enzymes released during tissue dissociation, hand picking of islets was not performed as a purification step (hand picking of islets requires at least 1 hour at room temperature). Alternatively, TSQ (6-methoxy-8-toluenesulfonamide-quinoline) was used for enrichment of endocrine cells by FACS sorting (Huch et al., 2013). Cells were resuspended in a solution containing TSQ (0.2 mg / ml). After FACS sorting, endocrine (TSQ + ) and non-endocrine (TSQ -) compartments were mixed together in a 1:1 ratio to form one sequencing sample. Cell quality was checked under a microscope before loading onto the 3' library chip and cell viability was ensured to be above 75% and that more than 90% of the cells were singlets. 13,000 single cells were loaded and recoveries were 3,706; 2,349; and 1,111 cells. for each biological replicate, respectively. The output ratio of the endocrine compartment to the non-endocrine compartment was higher than 1:1. This may be due to the relatively large size of acinar cells, resulting in their underrepresentation when using the 10X Genomics approach (see below).
[0177] To retrieve the transplanted cells for sequencing, the grafts were carefully dissected from the kidneys and then minced and digested with trypsin-EDTA and DNase I. + The cells were FACS sorted, sequenced, and then compared to primary mouse islet cells. 13,000 transplanted cells collected from three recipient mice (one mouse transplanted with organoid 7 and two mice transplanted with organoid 15) were loaded, and 2,129 cells were recovered.
[0178] For library preparation, single cells were loaded onto the 3' library chip of the Chromium Single Cell 3' Library (V2) according to the manufacturer's recommendations (10X Genomics). Briefly, single cells were sorted onto gel beads in emulsion in the GemCode instrument for cell lysis and barcoded reverse transcription of RNA followed by amplification, shearing, and ligation of 5' adapters and sample indexes. Libraries were sequenced on an Illumina HiSeq PE150.
[0179] Filtering (multiplexing), alignment to the mm10 transcriptome, and unique molecular identifier (UMI)-folding were performed using the Cell Ranger (V2) pipeline (10X Genomics). The Seurat 3R package was used for data integration, analysis, and visualization as described by Butler et al. in Nat Biotechnol 36, 411-420 (2018), the contents of which are incorporated herein by reference in their entirety. Specifically, Seurat objects were created by selecting genes expressed in at least two cells and cells for which at least 300 genes were detected and 3,000 UMIs were detected. Only 6 cells were filtered from replicate 3 primary pancreatic samples (from 1,111 cells to 1,105 cells). In the case of E14.5 Ngn3 from Byrnes et al., Nat Commun 9, 3922 (2018) and Scavuzzo et al., Nat Commun 9, 3356 (2018), the Seurat 3R package was used for data integration, analysis, and visualization as described by Butler et al. in Nat Biotechnol 36, 411-420 (2018), the contents of which are incorporated herein by reference in their entirety. Specifically, Seurat objects were created by selecting genes expressed in at least two cells and cells for which at least 300 genes were detected and 3,000 UMIs were detected. +In the analysis of single-cell RNA sequencing data (the respective contents are incorporated herein by reference in their entirety), the same filtering criteria were used for the creation of Seurat objects, and Ngn3 + cells were filtered by Neurog3 UMI > 0. Variable genes were identified using the "vst" method, and the top 2000 genes were selected for principal component analysis (PCA). Dimensionality reduction was performed using the t-stochastic neighbor embedding method (tSNE). The top 20 principal components (PCs) were used. Cell clusters were based on the shared nearest neighbor (SNN) method, with the resolution value for primary cells or primary VS transplanted cells set to 0.9, and the resolution value for primary VS E14.5 Ngn3 + cells set to 0.8. Based on the similarity of expression profiles and marker genes, some clusters were combined into one cell type. For data visualization, violin plots, heatmaps, dot plots, and individual tSNE plots of a given gene were generated using the Seurat toolkit VlnPlot, DoHeatmap, DotPlot, and FeaturePlot functions, respectively.
[0180] As described by Qui et al. in Nat Methods 14,979-982 (2017), pseudotime analysis of primary pancreatic cells was performed using the Monocle 2 R package, the content of which is incorporated herein by reference in its entirety. Alpha, beta, delta, PP, and the new cell populations were directly transferred from Seurat to Monocle 2 to create a monocle CellDataSet object, and 321 cells were further filtered. The top 2,000 variable genes identified by Seurat were used as ordering genes. Dimensionality reduction was performed using the "DDRTree" method, with max_components set to 2, to generate a bifurcation point. Split heatmaps were generated from the selected genes that showed significant changes during pseudotime (q value < E-10).
[0181] Statistics
[0182] Unpaired two-tailed Student's t-tests were performed, and p-values were calculated using GraphPad PRISM 6 when comparing two groups of samples. For all experiments with error bars, the standard error of the mean (SEM) was calculated to indicate the variation in each experiment.
[0183] Data availability
[0184] Single-cell RNA sequencing data are available at the website www.biosino.org / node / index, with access numbers NO.OEP000249 and OEP000250.
[0185] Example 2: Long-term culture and expansion of human islet organoids
[0186] Transplantation of islets and whole pancreases from cadaveric organ donations provides proof of concept that glucose homeostasis is restored after replenishment of the disease-causing β-cell deficiency (Lysy et al., 2013). The scarcity of donors has led to the search for strategies to generate β-cells in vitro. It has proven challenging to make new β-cells in vitro. Cell therapy for diabetes requires the identification of candidate cell sources and new culture strategies. Our previous studies in the murine pancreas (see Example 1) identified a new population of endocrine progenitor cells. These cells do not express pancreatic differentiation markers and can be sorted from islets based on expression of surface protein C receptor (Procr). These cells can form islet-like organoids in culture, respond to glucose, secrete insulin, and can expand long-term. In the current study, we took advantage of the existence of this endocrine progenitor cell population in humans and its significance in generating new human β-like cells in vitro.
[0187] To detect PROCR in human pancreatic islets + ProcR was immunostained in human pancreatic sections to detect the presence of procR in pancreatic islets. + Islet cells ( Fig. 8A ). Interestingly, these PROCR + The cells, similar to their mouse counterparts, do not express markers of endocrine differentiation ( Fig. 8A Procr is also found in the exocrine compartment of the human pancreas. + cell( Figure 8B ).
[0188] Next, these PROCRs were isolated and cultured. + Islet cells. Human pancreatic islets were obtained by collagenase perfusion and density gradient centrifugation followed by manual sorting and purification. We were unable to isolate Procr from primary islets because Procr was either cleaved from the cell surface or internalized during collagenase perfusion. + However, by experimenting with collagenase and other conditions, we believe that it is possible to isolate PROCR using anti-PROCR antibodies from human islets. + Cells were cultured similarly to the mouse experiments in Example 1. However, total pancreatic islet cells from humans were cultured. For this purpose, isolated (dissociated) single cells were stained with TSQ (6-methoxy-8-toluenesulfonamide-quinoline, a fluorescent zinc indicator used to enrich for endocrine cells) and sorted by FACS for TSQ. + Representative FACS profiles showing three different levels of TSQ uptake in human islet samples, TSQ-high, TSQ-low, and TSQ-negative ( Fig.9A). The three groups were sorted and then cytospinned and stained for endocrine (INS, GCG) and exocrine (AMY, KRT19) markers. We found that high TSQ scores also showed abundant exocrine marker expression ( Fig. 9B ), consistent with the findings in mice.
[0189] Next, TSQ-high cells (endocrine / islet cells) were sorted and cultured in 3D culture from various donor tissues ( Fig. 9C To establish a human islet cell culture medium, small molecules and growth factors were screened on the basis of the basal medium used for mouse islet organoid culture (DMEM / F12+EGF+ITS+FGF2+Heparin+B27), including Wnt agonist CHIR99021 or NGS (Wnt pathway activating peptide), TGF-β pathway inhibitor SB431542 or A83-01, Rho-ROCK pathway inhibitor Y27632, Bmp agonist Bmp2 or Bmp inhibitor Noggin to support growth ( Figures 10A-10C Based on the colony formation rate and colony / organoid size, growth-promoting conditions (DMEM / F12+EGF+ITS+FGF2+Heparin+Y27632+B27+CHIR99021+Noggin+A83-01) were established, which required activation of Wnt, FGF, and BMP signaling and inhibition of TGFβ and Rho-ROCK pathways ( Fig. 10C ). Activating integrin beta1 antibody (1 nM) also facilitated growth. Organoids formed under this culture condition contained most of the INS + β-like cells and small amounts of GCG + α-like cells ( Fig. 10D ), similar to the cellular composition of human pancreatic islets.
[0190] Islet organoids were generated from three different donors. Organoid formation efficiency was consistently around 0.8% ( Fig.11A ), indicating that organoids are unlikely to be formed from contaminating non-endocrine cells. In fact, endocrine islet organoids and exocrine ductal organoids exhibit different phenotypes. Islet organoids are more compact and have a "bunch of grapes" structure similar to pancreatic islets ( Fig. 11B (Day 12)), while ductal organoids showed a typical "ring-like" structure ( Fig. 11B (Day 14)). On culture day 18, organoids ranged in size from 50 to 300 μm ( Fig. 11C When dissociated into single cells and replated under the same culture conditions, organoids expanded 3-9-fold during each passage ( Fig. 11C), the average size of the organoids decreased slightly after passage and remained stable over many passages ( Figures 11C-11D ).
[0191] Insulin (INS) expression was examined as an indicator of functional β-cell formation. Whole mount immunostaining was performed in primary organoids. The majority of organoid cells showed high levels of insulin ( Figures 12A-12B ). These organoids also contain small amounts of GCG + α-like cells ( Figures 12A-12B ), similar to what was observed in mouse islet organoids. Unlike ductal organoids, which showed expression of the ductal marker SOX9 ( Fig. 12C ), pancreatic islet organoids do not express SOX9 ( Figures 12A-12B ). In addition, these pancreatic organoids can respond strongly to glucose. Organoid cells rapidly increase cytosolic Ca in response to glucose. 2+ concentration and then returned to baseline ( Fig.12D Insulin expression was also confirmed in cultured organoids ( Fig.12E ), indicating that β-cell differentiation can be achieved after long-term culture and expansion.
[0192] EdU incorporation assays revealed the presence of a proliferating cell population within the organoids ( Fig.13A ), indicating the presence of proliferating / undifferentiated cells and differentiated hormone-expressing cells within the organoids. PROCR expression in these organoids was analyzed by FACS. Approximately 2.5% of cells in human pancreatic islet organoids are Procr + ( Fig. 13B ), similar to Procr found in mouse pancreatic islet organoids + In addition, with Procr - Compared with cells, Procr + Cells showed approximately 10-fold higher EdU incorporation ( Fig. 13C ), suggesting that these cells are more proliferative and may be the main contributors to organoid formation.
[0193] In summary, the data show that the methods and compositions described herein can generate functional human β-like cells in vitro. Isolated human islet cells can be grown at clonal density into islet-like organoids that contain various endocrine cell types, are able to detect glucose and secrete insulin. These organoids can be exponentially expanded in vitro through long-term serial passage.
[0194] method
[0195] Patients and methods
[0196] All human islets or specimens were obtained from Changzheng Hospital. The use of samples for research was approved by the ethics committee and the patients signed informed consent.
[0197] statistics
[0198] Unpaired two-tailed Student's t-tests were performed and when comparing two groups of samples, p-values were calculated using GraphPad PRISM 6. For all experiments with error bars, the standard error of the mean (SEM) was calculated to indicate the variation within each experiment.
[0199] Islet enrichment and purification
[0200] Human islet enrichment was performed by Changzheng Hospital according to standard protocols (density gradient centrifugation after perfusion). High-purity islets are used for clinical transplantation. Islets with lower purity (~5%-20%) were further enriched by hand selection and used in this study. According to TSQ staining and FACS analysis, the purity of islets ranged from ~20%-70%.
[0201] Preparation of pancreatic islet single cell suspension and FACS analysis
[0202] Purified islets were prepared by treating with 2 ml of 0.05% trypsin-EDTA at 37 °C for 5 min and 0.1 mg ml - 1 Treat with DNase I for another 5 minutes to obtain a single cell suspension by gently pipetting about 20 times, and then filter the cells through a 70 μm cell strainer.
[0203] For FACS analysis of PROCR, antibodies were incubated on ice for 25 min in HBSS containing 5% FBS at a dilution of 1:200. To exclude exocrine and other cell lineages, isolated single cells were resuspended in PBS containing TSQ (0.2 mg ml -1 ) in a solution containing 10% TSQ. Cells with high TSQ were sorted and cultured to ensure that the generated organoids were of endocrine origin. All analysis and sorting experiments were performed using FACS Jazz (Becton Dickinson). The purity of the sorted population was routinely checked to ensure that it was above 95%.
[0204] Establishment of a human pancreatic islet organoid generation and subculture system
[0205] 200 μl of Matrigel was coated in one well of a 48-well plate and transferred to a 37°C ESCO incubator for solidification. Human pancreatic cells with high TSQ were sorted by FACS and seeded in 500 μl of human organ culture medium, which consisted of DMEM / F12 (with penicillin-streptomycin) supplemented with 2% B27, 1% ITS, 50 ng ml -1 EGF, 2 μg ml -1 Heparin, 10 ng ml -1FGF2, 3μM CHIR99021, 2μM A83-01, 100ng ml -1 Noggin, 10 μM Y27632. The culture medium was renewed every 2-3 days.
[0206] Organoids were passaged every 7-21 days. For passage, organoids were released from the matrigel using dispase (37°C for 30 minutes) and dissociated into single cells using 1 ml of 0.05% trypsin-EDTA (37°C for 3-6 minutes). Single cells were then resuspended in culture medium and seeded at a split ratio of 1:3-1:8.
[0207] Immunofluorescence, whole mount staining, and microscopy
[0208] To prepare samples for cryosectioning, dissected pancreas were fixed in 4% PFA for 4 hours at 4°C, washed 3 times with PBS, and then embedded in optimal cutting temperature (OCT). Tissue sections were incubated with primary antibodies overnight at 4°C, then washed in PBST (PBS + 0.1% Triton-X 100), incubated with secondary antibodies and DAPI for 2 hours at room temperature, and then the sections were washed and mounted for confocal imaging.
[0209] For whole mount staining, human islets or cultured organoids were fixed in 4% PFA for 1 hour at 4°C, then washed three times with PBS and then blocked with whole mount blocking buffer for 1 hour at room temperature. The blocking buffer contained 10% FBS in PBST. Primary antibodies were diluted in blocking buffer and incubated overnight at 4°C, and after washing three times with PBST, secondary antibodies and DAPI were incubated overnight at 4°C. Islets or organoids were then washed and mounted with mounting medium for confocal imaging.
[0210] All confocal images were captured by a Leica SP8 confocal detection system mounted on a Leica DMI6000 microscope.
[0211] Example 3: Identification of human adult pancreatic endocrine / islet progenitor cells and in vitro culture into islet organoids
[0212] To identify potential endocrine progenitor cell populations in humans, we performed scRNA-seq using isolated pancreatic cells from 2 donors. They were combined with published human pancreas datasets (Baron et al., 2016; Enge et al., 2017; Grün et al., 2016; Lawlor et al., 2017; Muraro et al., 2016; Segerstolpe et al., 2016) and integrated with published mouse pancreas datasets ((Wang et al., 2020), also in Example 1). A total of 20,660 human cells (8 datasets) and 7,051 mouse cells (3 datasets) were analyzed ( Figures 14A-14B Each cluster was mapped to a cell type known to be abundant (α, β, δ, ε, and PP cells), abundant (acinar and ductal cells), or rare (endothelial cells, immune cells, dormant and active stellate cells) ( Figures 14A-14C Integrative approaches reveal potential endocrine progenitor clusters in human cells containing proteins similar to mouse Procr + Progenitor cell aggregates Figures 14A-14C The new human cell population showed unique signature genes, including UPK1B, S100A6, LGALS4, SDCBP2, SDC1, IGFBP3, HMGA1, ITGB4, ITGB6, HN1, GPRC5A, SLPI, LAMC2, FERMT1, MGLL, MSLN, SEMA3B, TST, SFN and CDH3 ( Figures 14D-14E ), but do not express known markers of endocrine or exocrine differentiation, as shown by t-distributed random neighbor embedding (t-SNE) analysis ( Fig. 14C Pseudo-temporal analysis using monocle2 predicted two developmental trajectories starting from endocrine progenitor cells: one towards β cells and one towards α cells ( Fig.14F ). To our surprise, PROCR was not found in the signature. + The cells have been confirmed by immunostaining of PROCR in human pancreatic sections ( Fig. 8A , Example 2). In the scRNA-seq analysis, the lack of PROCR in the identified features may be due to the low abundance of PROCR transcripts.
[0213] To search for more abundantly expressed markers that could be used to isolate this potential population of human endocrine progenitor cells, we screened for genes in a signature encoding surface proteins. We identified MSLN. Immunostaining of MSLN in human pancreatic sections confirmed its expression in a small population of islet cells ( Fig.15A ). These MSLN + Cells do not express insulin (INS) Fig.15ASmall amounts of MSLN can also be detected in exocrine acini and ducts. + cell( Fig. 15B ). Through FACS analysis, we found that MSLN + The cells consist of approximately 3-5% of the total pancreatic islet cells (TSQ-high, TSQ-hi) ( Fig. 15C ).MSLN + Cells can also be found in 0.5-1% of exocrine cells (TSQ-mid or TSQ-low) ( Fig. 15C Next, we compared the total TSQ-hi cells in the TSQ-hi compartment as well as the MSLN + and MSLN-cell sorting ( Fig.15A ) and cultured them under the conditions established in previous studies (Figure 10, in Example 2). We found that total TSQ-hi and TSQ-hi, MSLN + cells can form organoids, while MSLN- cells cannot ( Fig.15D ). Compared with total TSQ-hi cells, TSQ-hi, MSLN + Cells exhibited significantly higher (approximately 7-fold) organoid formation efficiency ( Fig.15D and Fig.15E ). These data suggest that MSLN + The cells are enriched for human pancreatic endocrine progenitor cells that are capable of forming organoids in vitro.
[0214] On day 14 of culture, we analyzed the isolated organoids by FACS. Interestingly, we found that most MSLN + Cells are also Procr + , double-positive cells accounted for 17% of all organoid cells ( Fig.15F ). This indicates that MSLN + and Procr + The cells were homogeneous populations, reinforcing the idea that PROCR depletion in scRNA-seq may be due to low abundance of PROCR transcripts.
[0215] In our previous work culturing mouse islet progenitor cells (in Example 1), co-culture with endothelial cells (EC) was critical for organoid formation. Next, we explored whether the addition of ECs would benefit the formation of human islet organoids. ECs were isolated from human pancreatic tissue based on CD31 or CD34 expression. Islet cells and ECs were mixed in ratios ranging from 5:1 to 1:1. In these experiments, VEGFa (50 ng / ml) was added to support EC growth. In the islet cell group alone, islet organoids were formed, with a size range of 45-100 μm ( Fig.16A and Fig. 16C Co-culture with ECs significantly increased the size of organoids, ranging from 80-180 μm on day 10 of culture ( Fig. 16B and Fig. 16C ). These results suggest that, although islet organoids can be maintained long-term under specific culture conditions (as shown in Example 2), co-culture with ECs can promote the growth of islet organoids, similar to what we found in mouse islet organoid culture.
[0216] Taken together, these data demonstrate that the methods and compositions described herein can 1) define human islet progenitor cells by the above characteristics, 2) isolate human islet progenitor cells based on surface MSLN expression, and 3) generate functional human β-like cells in vitro. Isolated human islet cells can be grown into islet-like organoids in vitro.
[0217] Other Implementations
[0218] From the foregoing description, it is obvious that the invention described herein may be varied and modified to adapt it to various usages and conditions. Such embodiments also fall within the scope of the claims herein.
[0219] Reference to a list of elements in any definition of a variable herein includes definitions of the variable as any single element or listed element combination (or subcombination). Reference to an embodiment herein includes the embodiment as any single embodiment or combination or part thereof with any other embodiment.
[0220] All patents and publications mentioned in this specification are herein incorporated by reference to the same extent as if each individual patent or publication was specifically and individually indicated to be incorporated by reference.
[0221] References
[0222] Al-Hasani, K., Pfeifer, A., Courtney, M., Ben-Othman, N., Gjernes, E., Vieira, A., Druelle, N., Avolio, F., Ravassard, P., Leuckx, G., et al. (2013). Adult duct-lining cells can reprogram into beta-like cells able to counter repeated cycles of toxin-induced diabetes. Dev Cell 26, 86-100.
[0223] Balazs, AB, Fabian, AJ, Esmon, CT, and Mulligan, RC (2006). Endothelial protein C receptor (CD201) explicitly identifies hematopoietic stem cells in murine bone marrow. Blood 107, 2317-2321.
[0224] Bonner-Weir, S., Taneja, M., Weir, GC, Tatarkiewicz, K., Song, KH, Sharma, A., and O'Neil, JJ (2000). In vitro cultivation of human islets from expanded ductal tissue. Proc Natl Acad Sci USA 97, 7999-8004.
[0225] Butler, A., Hoffman, P., Smibert, P., Papalexi, E., and Satija, R. (2018). Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol 36, 411-420.
[0226] Byrnes, LE, Wong, DM, Subramaniam, M., Meyer, NP, Gilchrist, CL, Knox, SM, Tward, AD, Ye, CJ, and Sneddon, JB (2018). Lineage dynamics of murine pancreatic development at single-cell resolution. Nat Commun 9, 3922.
[0227] Cheng, X., Ying, L., Lu, L., Galvao, AM, Mills, JA, Lin, HC, Kotton, DN, Shen, SS, Nostro, MC, Choi, JK, et al. (2012). Self-renewing endodermal progenitor lines generated from human pluripotent stem cells. Cell Stem Cell 10, 371-384.
[0228] Criscimanna, A., Speicher, J. A., Houshmand, G., Shiota, C., Prasadan, K., Ji, B., Logsdon, C. D., Gittes, G. K., and Esni, F. (2011). Duct cells contribute to regeneration of endocrine and acinar cells following pancreatic damage in adult mice. Gastroenterology 141, 1451-1462, 1462e1451-1456.
[0229] Fares, I., Chagraoui, J., Lehnertz, B., MacRae, T., Mayotte, N., Tomellini, E., Aubert, L., Roux, PP, and Sauvageau, G. (2017). EPCR expression marks UM171-expanded CD34+ cord blood stem cells. Blood 129, 3344-3351.
[0230] Furuyama, K., Kawaguchi, Y., Akiyama, H., Horiguchi, M., Kodama, S., Kuhara, T., Hosokawa, S., Elbahrawy, A., Soeda, T., Koizumi, M., et al. (2011). Continuous cell supply from a Sox9-expressing progenitor zone in adult liver, exocrine pancreas and intestine. Nat Genet 43, 34-41.
[0231] Gao, R., Ustinov, J., Korsgren, O., and Otonkoski, T. (2005). In vitro neogenesis of human islets reflects the plasticity of differentiated human pancreatic cells. Diabetologia 48, 2296-2304.
[0232] Gehart, H., van Es, J. H., Hamer, K., Beumer, J., Kretzschmar, K., Dekkers, J. F., Rios, A., and Clevers, H. (2019). Identification of Enteroendocrine Regulators by Real-Time Single-Cell Differentiation Mapping. Cell 176, 1158-1173e1116.
[0233] Gershengorn, MC, Hardikar, AA, Wei, C., Geras-Raaka, E., Marcus-Samuels, B., and Raaka, BM (2004). Epithelial-to-mesenchymal transition generates proliferative human islet precursor cells. Science 306, 2261-2264.
[0234] Greggio, C., De Franceschi, F., Figueiredo-Larsen, M., Gobaa, S., Ranga, A., Semb, H., Lutolf, M., and Grapin-Botton, A. (2013). Artificial three-dimensional niches deconstruct pancreas development in vitro. Development 140, 4452-4462.
[0235] Gu, G., Dubauskaite, J., and Melton, DA (2002). Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. Development 129, 2447-2457.
[0236] Hardikar, AA (2016). Pancreatic Islet Biology, 1 edn (Switzerland: Springer International Publishing).
[0237] Huch, M., Bonfanti, P., Boj, S. F., Sato, T., Loomans, C. J., van de Wetering, M., Sojoodi, M., Li, V. S., Schuijers, J., Gracanin, A., et al. (2013). Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5 / R-spondin axis. EMBO J 32, 2708-2721.
[0238] Inada, A., Nienaber, C., Katsuta, H., Fujitani, Y., Levine, J., Morita, R., Sharma, A., and Bonner-Weir, S. (2008). Carbonic anhydrase II-positive pancreatic cells are progenitors for both endocrine and exocrine pancreas after birth. Proc Natl Acad Sci U SA 105, 19915-19919.
[0239] Iwasaki, H., Arai, F., Kubota, Y., Dahl, M., and Suda, T. (2010). Endothelial protein C receptor-expressing hematopoietic stem cells reside in the perisinusoidal niche in fetal liver. Blood 116, 544-553.
[0240] Jin, L., Feng, T., Shih, HP, Zerda, R., Luo, A., Hsu, J., Mahdavi, A., Sander, M., Tirrell, DA, Riggs, AD, et al. (2013). Colony-forming cells in the adult mouse pancreas are expandable in Matrigel and form endocrine / acinar colonies in laminin hydrogel. Proc Natl Acad Sci USA 110, 3907-3912.
[0241] Kopp, JL, Dubois, CL, Schaffer, AE, Hao, E., Shih, HP, Seymour, PA, Ma, J., and Sander, M. (2011). Sox9+ductal cells are multipotent progenitors throughout development but do not produce new endocrine cells in the normal or injured adult pancreas. Development 138, 653-665.
[0242] Lammert, E., Cleaver, O., and Melton, D. (2001). Induction of pancreatic differentiation by signals from blood vessels. Science 294, 564-567.
[0243] Lysy, PA, Weir, GC, and Bonner-Weir, S. (2013). Making beta cells from adult cells within the pancreas. Curr Diab Rep 13, 695-703.
[0244] Minami, K., Okuno, M., Miyawaki, K., Okumachi, A., Ishizaki, K., Oyama, K., Kawaguchi, M., Ishizuka, N., Iwanaga, T., and Seino, S. (2005). Lineage tracing and characterization of insulin-secreting cells generated from adult pancreatic acinar cells. Proc Natl Acad Sci USA 102, 15116-15121.
[0245] Mohammed, JS, Wang, Y., Harvat, TA, Oberholzer, J., and Eddington, DT (2009). Microfluidic device for multimodal characterization of pancreatic islets. Lab Chip 9, 97-106.
[0246] Ouziel-Yahalom, L., Zalzman, M., Anker-Kitai, L., Knoller, S., Bar, Y., Glandt, M., Herold, K., and Efrat, S. (2006). Expansion and redifferentiation of adult human pancreatic islet cells. Biochem Biophys Res Commun 341, 291-298.
[0247] Pagliuca, FW, Millman, JR, Gurtler, M., Segel, M., Van Dervort, A., Ryu, JH, Peterson, QP, Greiner, D., and Melton, DA (2014). Generation of functional human pancreatic beta cells in vitro. Cell 159, 428-439.
[0248] Pan, F.C., Bankaitis, E.D., Boyer, D., Xu, X., Van de Casteele, M., Magnuson, M.A., Heimberg, H., and Wright, C.V. (2013). Spatiotemporal patterns of multipotentiality in Ptf1a-expressing cells during pancreas organogenesis and injury-induced facultative restoration. Development 140, 751-764.
[0249] Pan, FC, and Wright, C. (2011). Pancreas organogenesis: from bud to plexus to gland. Dev Dyn 240, 530-565.
[0250] Qiu, X., Mao, Q., Tang, Y., Wang, L., Chawla, R., Pliner, H. A., and Trapnell, C. (2017). Reversed graph embedding resolves complex single-cell trajectories. Nat Methods 14, 979-982.
[0251] Ramiya, VK, Maraist, M., Arfors, KE, Schatz, DA, Peck, AB, and Cornelius, JG (2000). Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells. Nat Med 6, 278-282.
[0252] Rezania, A., Bruin, JE, Arora, P., Rubin, A., Batushansky, I., Asadi, A., O'Dwyer, S., Quiskamp, N., Mojibian, M., Albrecht, T., et al. (2014). Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat Biotechnol 32, 1121-1133.
[0253] Rovira, M., Scott, SG, Liss, AS, Jensen, J., Thayer, SP, and Leach, SD (2010). Isolation and characterization of centroacinar / terminal ductal progenitor cells in adult mouse pancreas. Proc Natl Acad Sci USA 107, 75-80.
[0254] Rukstalis, JM, and Habener, JF (2007). Snail2 is a mediator of epithelial-mesenchymal transitions, expressed in progenitor cells of the developing endocrine pancreas. Gene Expr Patterns 7, 471-479.
[0255] Russ, HA, Bar, Y., Ravassard, P., and Efrat, S. (2008). In vitro proliferation of cells derived from adult human beta-cells revealed by cell-lineage tracing. Diabetes 57, 1575-1583.
[0256] Scavuzzo, MA, Hill, MC, Chmielowiec, J., Yang, D., Teaw, J., Sheng, K., Kong, Y., Bettini, M., Zong, C., Martin, J. F., et al. (2018). Endocrine lineage biases arise intemporally distinct endocrine progenitors during pancreatic morphogenesis. Nat Commun 9, 3356.
[0257] Seaberg, RM, Smukler, SR, Kieffer, TJ, Enikolopov, G., Asghar, Z., Wheeler, MB, Korbutt, G., and van der Kooy, D. (2004). Clonal identification of multipotent precursors from adult mouse pancreas that generate neural and pancreatic lineages. Nat Biotechnol 22, 1115-1124.
[0258] Smukler, SR, Arntfield, ME, Razavi, R., Bikopoulos, G., Karpowicz, P., Seaberg, R., Dai, F., Lee, S., Ahrens, R., Fraser, PE, et al. (2011). The adult mouse and human pancreas contain rare multipotent stem cells that express insulin. Cell Stem Cell 8, 281-293.
[0259] Sneddon, JB, Borowiak, M., and Melton, DA (2012). Self-renewal of embryonic-stem-cell-derived progenitors by organ-matched mesenchyme. Nature 491, 765-768.
[0260] Sugiyama, T., Benitez, CM, Ghodasara, A., Liu, L., McLean, GW, Lee, J., Blauwkamp, TA, Nusse, R., Wright, CV, Gu, G., et al. (2013). Reconstituting pancreas development from purified progenitor cells reveals genes essential for islet differentiation. Proc Natl Acad Sci USA 110, 12691-12696.
[0261] Van de Casteele, M., Leuckx, G., Baeyens, L., Cai, Y., Yuchi, Y., Coppens, V., DeGroef, S., Eriksson, M., Svensson, C., Ahlgren, U., et al. (2013). Neurogenin 3+ cells contribute to beta-cellneogenesis and proliferation in injured adult mouse pancreas. Cell Death Dis 4, e523.
[0262] Wang, D., Cai, C., Dong, X., Yu, Q. C., Zhang, X. O., Yang, L., and Zeng, Y. A. (2015). Identification of multipotent mammary stem cells by protein C receptor expression. Nature 517, 81-84.
[0263] Xu, X., D'Hoker, J., Stange, G., Bonne, S., De Leu, N., Xiao, X., Van de Casteele, M., Mellitzer, G., Ling, Z., Pipeleers, D., et al. (2008). Beta cells can be generated from endogenous progenitors in injured adult mouse pancreas. Cell 132, 197-207.
[0264] Yatoh, S., Dodge, R., Akashi, T., Omer, A., Sharma, A., Weir, G.C., and Bonner-Weir, S. (2007). Differentiation of affinity-purified human pancreatic duct cells to beta-cells. Diabetes 56, 1802-1809.
[0265] Yu, QC, Song, W., Wang, D., and Zeng, YA (2016). Identification of blood vascular endothelial stem cells by the expression of protein C receptor. Cell Res 26, 1079-1098.
[0266] Zhou, F., Li, X., Wang, W., Zhu, P., Zhou, J., He, W., Ding, M., Xiong, F., Zheng, X., Li, Z., et al. (2016). Tracing haematopoietic stem cell formation at single-cell resolution. Nature 533, 487-492.
[0267] Baron, M., Veres, A., Wolock, Samuel L., Faust, Aubrey L., Gaujoux, R., Vetere, A., Ryu, Jennifer H., Wagner, Bridget K., Shen-Orr, Shai S., Klein, Allon M., et al. (2016). A Single-Cell Transcriptomic Map of the Human and Mouse Pancreas Reveals Inter- and Intra-cell Population Structure. Cell Systems 3, 346-360. e344.
[0268] Enge, M., Arda, HE, Mignardi, M., Beausang, J., Bottino, R., Kim, SK, and Quake, SR (2017). Single-Cell Analysis of Human Pancreas Reveals Transcriptional Signatures of Aging and Somatic Mutation Patterns. Cell 171, 321-330. e314.
[0269] Grün, D., Muraro, Mauro J., Boisset, J.-C., Wiebrands, K., Lyubimova, A., Dharmadhikari, G., van den Born, M., van Es, J., Jansen, E., Clevers, H., et al. (2016). De Novo Prediction of Stem Cell Identity using Single-Cell Transcriptome Data. Cell Stem Cell 19, 266-277.
[0270] Lawlor, N., George, J., Bolisetty, M., Kursawe, R., Sun, L., Sivakamasundari, V., Kycia, I., Robson, P., and Stitzel, M. L. (2017). Single-cell transcriptomes identify human islet cell signatures and reveal cell-type–specific expression changes in type 2 diabetes. Genome Research 27, 208-222.
[0271] Muraro, Mauro J., Dharmadhikari, G., Grün, D., Groen, N., Dielen, T., Jansen, E., van Gurp, L., Engelse, Marten A., Carlotti, F., de Koning, Eelco JP, et al. (2016). A Single-Cell Transcriptome Atlas of the Human Pancreas. Cell Systems 3, 385-394.e383.
[0272] Segerstolpe, Palasantza, A., Eliasson, P., Andersson, E.-M., Andréasson, A.-C., Sun, X., Picelli, S., Sabirsh, A., Clausen, M., Bjursell, MK, et al. (2016). Single-Cell Transcriptome Profiling of Human Pancreatic Islets in Health and Type 2 Diabetes. Cell Metabolism 24, 593-607.
[0273] Wang, D., Wang, J., Bai, L., Pan, H., Feng, H., Clevers, H., and Zeng, Y. A. (2020). Long-Term Expansion of Pancreatic Islet Organoids from Resident Procr(+) Progenitors. Cell 180, 1198-1211e1119.
Claims
1. A culture medium and method for producing pancreatic organoids in vitro, It is characterized in that The method comprises: providing endocrine progenitor cells; and The endocrine progenitor cells are cultured in vitro in an organoid medium under conditions suitable for producing pancreatic organoids containing functional β cells and / or β-like cells. Preferably, the organoid medium further comprises a three-dimensional matrix such as Matrigel. TM and hydrogels.
2. The method according to claim 1, It is characterized in that The endocrine progenitor cells are isolated from adult pancreatic islet cells.
3. The method according to claim 1, It is characterized in that The endocrine progenitor cells are provided within a population of adult pancreatic islet cells.
4. The method according to any one of claims 1 to 3, It is characterized in that The adult pancreatic islet cells are of human origin, and the endocrine progenitor cells are MSLN+, wherein, optionally, the endocrine progenitor cells also express one or more of UPK1B, S100A6, LGALS4, SDCBP2, SDC1, IGFBP3, HMGA1, ITGB4, ITGB6, HN1, GPRC5A, SLPI, LAMC2, FERMT1, MGLL, SEMA3B, TST, SFN, CDH3 and PROCR.
5. The method according to claim 4, It is characterized in that The method further comprises: contacting the isolated adult human islet cells with an anti-MSLN antibody or an antigen-binding fragment thereof in vitro, followed by fluorescence-assisted cell sorting (FACS) to isolate the endocrine progenitor cells.
6. The method according to claim 4, It is characterized in that The organoid culture medium comprises a basal medium such as DMEM / F12, and is supplemented with one or more of the following: 10-200 (e.g. 50) ng ml-1 EGF, 1-50 (e.g. 10) ng ml-1 -1 FGF2, 1-10 (e.g. 3) μM Wnt agonist such as CHIR99021 or 1-100 (e.g. 30) ng / ml Wnt surrogate such as NGS (Next Generation Surrogate), 0.1-5 (e.g. 0.5) μM TGF-beta pathway inhibitor such as SB431542 or A83-01, 10-500 (e.g. 100) ng / ml -1 Bmp inhibitors such as Noggin, 1-10 (e.g. 2.5) μM Rock inhibitors such as Y27632, and 1-10 (e.g. 0.5) μM p38 inhibitor SB202190; wherein, optionally, the basal medium is also supplemented with one or more of the following: 1-5% (e.g. 2%) B27, 0.1-5% (e.g. 1%) ITS, 0.1-5 (e.g. 2) μg ml -1 Heparin and 1-100 (e.g. 50) ng ml - 1 VEGFa.
7. The method according to any one of claims 1 to 3, in, The adult pancreatic islet cells are of mouse origin, and the endocrine progenitor cells are Procr + , the 3D culture comprises co-culture with a plurality of endothelial cells, wherein, optionally, the endocrine progenitor cells also express one or more of Rspo1, Fgf1, Upk3B, Hoxa5 and Msln.
8. The method according to claim 7, It is characterized in that The method further comprises contacting the isolated adult mouse pancreatic islet cells with an anti-Procr antibody or an antigen-binding fragment thereof in vitro, followed by fluorescence-assisted cell sorting (FACS) to isolate the endocrine progenitor cells.
9. The method according to claim 7, It is characterized in that The culture medium comprises a basic medium such as DMEM / F12, supplemented with one or more of the following: 10-200 (e.g. 50) ng ml -1 EGF, 1-50 (e.g. 10) ng ml -1 FGF2 and 1-20 (e.g. 5) ng ml -1 VEGFa; optionally, the basal medium is also supplemented with one or more of the following: 1-5% (e.g. 2%) B27, 0.1-5% (e.g. 1%) ITS, and 0.1-5 (e.g. 2) μg ml -1 heparin.
10. The method according to any one of claims 1 to 9, It is characterized in that The culturing step includes culturing until the endocrine progenitor cells form colonies with a diameter of about 100-300 μm, and continuing to culture the colonies to form pancreatic organoids with a diameter of about 150-500 μm.
Citation Information
Patent Citations
Biomarker and Therapeutic Target for Triple Negative Breast Cancer
US20190045758A1
Immunoglobulins devoid of light chains
US5759808A
Immunoglobulins devoid of light chains
US5800988A
Immunoglobulins devoid of light chains
US5840526A
Immunoglobulins devoid of light chains
US5874541A
